Department Metrics

• Novel Immunotherapy for Brain-Metastatic Breast Cancer
  Award Number:
  Sponsor: US Army
  PI:Czerniecki, B.
• Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Hwu, P.
• Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Heterogeneity of metastatic small cell lung cancer; implications for the design of effective immunotherapies
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Beg, A.,PI (MPI):Haura, E.
• Tissue-Anchored vs. Circulating Constructs for Immunometabolic Resolution of Psoriasis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Targeting dendritic cells to improve cancer immunotherapy
  Award Number:
  Sponsor: Cancer Research Institute
  PI:Ruffell, B.
• A Clinical Trial of Pirtobrutinib and Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Jain, M.
• Bench-bedside-bidirectional investigation of a new combinatorial immunotherapy strategy to treat platinum-resistant penile cancer
  Award Number:
  Sponsor: US Army
  PI:Chahoud, J.
• Dissecting the spatial molecular architecture of the transformed cutaneous T-cell lymphoma tumor microenvironment to target novel therapeutic vulnerabilities
  Award Number:
  Sponsor: US Army
  PI (Contact):Chen, P.
• Defining Impact of in SITU Activation of CD40 and Type 1 Interferon Signaling on theTME and Systemic T Cell Immunity in Murine models and cancer patients
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Progressive immune dysfunction with advancing disease stage and immune changes post therapy in penile carcinoma
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Chahoud, J.
• Evaluating B-T cell crosstalk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade
  Award Number:
  Sponsor: US Army
  PI:Karapetyan, L.
• Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers – UG1
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Pidala, J.
• Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Perna, F.
• Metabolic and Molecular Regulation of Myeloid Cell Functions in Brain Cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Yu, X.
• Regulation of transcriptional programs in mouse and human tumor infiltrating CD8+ T cells
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Zelenka, T.
• Moffitt ACS Post-Baccalaureate Diversity in Cancer Research (MAP-DICR)
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• ENCOURAGE Diversity
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• Cancer screening behaviors among people with and without HIV in All of Us
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,Project PI:Islam, J.

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 21213
A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase pegol in Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: Calaspargase pegol ()

CLINICAL TRIAL 21341
A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Ziv-aflibercept ()

CLINICAL TRIAL 21351
A Prospective Analysis of Biochemical Markers for Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy in Adults
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 21448
Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Condition: Breast
Intervention:

CLINICAL TRIAL 21636
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Bempegaldesleukin (); Ipilimumab (); Midazolam (); NKTR-214 (Bempegaldesleukin); Nivolumab (Opdivo); Prednisone or Prednisolone (); Relatlimab (); Taxotere (docetaxel); Warfarin (); XL092 (); Yervoy (Ipilimumab); Zanzalintinib (); caffeine (); coumadin (Warfarin); docetaxel (); omeprazole (Prilosec)

CLINICAL TRIAL 21676
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases (TARGET-TNBC)
Condition: Breast
Intervention: Sacituzumab Govitecan (); Zimberelimab ()

CLINICAL TRIAL 21757
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
Condition: Breast
Intervention: Radiotherapy ()

CLINICAL TRIAL 21763
MRKR-21-401-OTS - A Phase 1 Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cells (MT-401-OTS) Administered to Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Bendamustine (); MESNA (); MT-401-OTS (); cyclophosphamide (); cytoxan (cyclophosphamide); decitabine (5-aza-2'-deoxycytidine); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22079
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOC-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Condition: Cutaneous
Intervention: IL-2 (Interleukin-2); IOV-4001 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22114
Randomized Phase II study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft vs. Host Disease
Condition: Malignant Hematology
Intervention: Belumosudil (); KD025 (Belumosudil); Placebo ()

CLINICAL TRIAL 22286
Phase 2 Study of KTE-X19 in MRD Positive B-ALL
Condition: Malignant Hematology
Intervention: KTE-X19 (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()

CLINICAL TRIAL 22505
Cutaneous Adverse Events (irCAEs) Associated with Immunotherapy in Patients with Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 22536
Immune Profiling of Relatlimab and Nivolumab Combination Immunotherapy for Advanced Stage Metastatic Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 22554
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Condition: Cutaneous
Intervention: Albumin-Bound Paclitaxel (); BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); IL-2 (Interleukin-2); IMA203 (); Ipilimumab (); Lifileucel (); Nivolumab (Opdivo); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Relatlimab (); Taxol (paclitaxel); Temodal (Temozolomide); Temozolomide (); Yervoy (Ipilimumab); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); paclitaxel ()

CLINICAL TRIAL 22574
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 23082
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2 (); Proleukin (Interleukin-2); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23184
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy (CARIsMA)
Condition: Malignant Hematology
Intervention: Placebo ()

CLINICAL TRIAL 23229
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants with HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Condition: Multiple
Intervention: Lenti-HPV-07 ()

CLINICAL TRIAL 23275
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23240
A Phase 1, Open Label Single-Arm Two-Part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy Of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subjects with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway And With Other Solid Tumors
Condition: Cutaneous
Intervention: NST-628 ()

CLINICAL TRIAL 23652
A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Condition: Malignant Hematology
Intervention: Rapamycin (Sirolimus); UB-VV111 ()

CLINICAL TRIAL 23340
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Condition: Breast
Intervention: Alisertib (MLN8237); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Letrozole (); Tamoxifen (); fulvestrant ()

CLINICAL TRIAL 23421
A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Placebo (); Vitamin A ()

CLINICAL TRIAL 23433
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer following Neoadjuvant Chemotherapy and Surgery
Condition: Breast
Intervention:

CLINICAL TRIAL 23449
A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23455
A phase I/IB study of Ropeginterferon in patients with Cutaneous T-Cell Lymphoma (CTCL)
Condition: Malignant Hematology
Intervention: Ropeginterferon alfa-2b (P1101) ()

CLINICAL TRIAL 23453
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: AZD0486 ()

CLINICAL TRIAL 23598
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Condition: Genitourinary
Intervention: Sacituzumab tirumotecan ()

CLINICAL TRIAL 23641
A Phase 2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Condition: Malignant Hematology
Intervention: Vimseltinib ()

CLINICAL TRIAL 23519
Integration of Machine Learning and Genomics to Predict Outcomes for Newly Diagnosed, Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms: A Global Study of the PETAL Consortium
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23572
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Condition: Breast
Intervention: Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen ()

CLINICAL TRIAL 23624
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies
Condition: Malignant Hematology
Intervention: Sonrotoclax (); Zanubrutinib ()

CLINICAL TRIAL 23645
PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF XB628 AS A SINGLE AGENT AND IN COMBINATION WITH ZANZALINTINIB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Condition: Multiple
Intervention: XB628 (); Zanzalintinib ()

CLINICAL TRIAL 23647
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Condition: Head & Neck
Intervention: PYX-201 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23706
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (Yescarta)

CLINICAL TRIAL 23735
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Condition: Malignant Hematology
Intervention: lisocabtagene maraleucel ()

CLINICAL TRIAL 23745
A Phase 1, First-in-Human Study of MEN2312, A KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Condition: Breast
Intervention: Capivasertib (); Elacestrant (); Faslodex (fulvestrant); MEN2312 (); everolimus (RAD001); fulvestrant ()

CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()

CLINICAL TRIAL 23814
A Phase 2 Trial of ORCA-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: ORCA-T (); Thiotepa (Thioplex); Total body irradiation (TBI) (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23829
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: TAK-505 ()

CLINICAL TRIAL 23833
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination with Anti-lymphoma Agents in Participants with Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Condition: Malignant Hematology
Intervention: BMS-986458 (); Glofitamab (); Mosunetuzumab (); Obinutuzumab (); Rituxan (rituximab); rituximab ()

CLINICAL TRIAL 23835
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC)
Condition: Breast
Intervention: Herceptin (Trastuzumab); T-DM1 (); T-Dxd (); Trastuzumab (); Xeloda (capecitabine); Zanidatamab (); Zongertinib (); capecitabine (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 23901
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052667 as a Single Agent and in Combination Therapy in Participants 18 Years of age and Older with Bladder Cancer
Condition: Genitourinary
Intervention: BCG (); PF-02921367 (); PF-06801591 (Sasanlimab); PF-08052667 (); Sasanlimab ()

CLINICAL TRIAL 23916
Phase II Study of Ruxolitinib-Based Primary Treatment for Acute GvHD
Condition: Malignant Hematology
Intervention: Jakafi (Ruxolitinib); Methylprednisolone (); Ruxolitinib ()

CLINICAL TRIAL 23939
Distinguishing Breast and Cutaneous Tumors
Condition: Breast
Intervention:

CLINICAL TRIAL 23993
A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients with Relapsed or Refractory Advanced Solid Tumors
Condition: Multiple
Intervention: IMGS-001 ()

CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 24030
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
Condition: Breast
Intervention:

CLINICAL TRIAL 24027
A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR'S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Condition: Malignant Hematology
Intervention: Bendamustine (); CC-5013 (Lenalidomide); Glofitamab (); Lenalidomide (Revlimid); Rituxan (rituximab); Tocilizumab (); rituximab ()

CLINICAL TRIAL 24043
Single Patient - Expanded Access Use of AMTAGVI
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 24096
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Condition: Breast
Intervention: 772256 (Palbociclib); Abemaciclib (); BGB-43395 (); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Ribociclib ()

CLINICAL TRIAL 24145
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple Myeloma
Condition: Immunotherapy
Intervention: KLN-1010 ()

CLINICAL TRIAL 24154
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination with Imatinib in Participants with Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
Condition: Sarcoma
Intervention: Imatinib (); KQB198 ()

CLINICAL TRIAL 24179
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy ENAiBLE
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 24191
A Phase 1, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Condition: Head & Neck
Intervention: REM-422 ()

CLINICAL TRIAL 24192
An Expanded Access Program for Orca-T Products That Are Out of Specification for Commercial Release
Condition: Malignant Hematology
Intervention: ORCA-T ()

CLINICAL TRIAL 24266
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention: ACP-196 (Acalabrutinib); Acalabrutinib (); GDC-0199 (Venetoclax); Sonrotoclax (); Venetoclax (); Zanubrutinib ()

CLINICAL TRIAL 24393
Establishing Melanoma PDXs for Neoantigen TCR Testing
Condition: Immunotherapy
Intervention:

• Clarke-Brodber AL, Chen PL, Ulhaque A, Rosa M, Cano Munoz CA. Breast implant-associated squamous cell carcinoma (BIA-SCC): Clinicopathologic analysis of two cases with radiologic-pathologic correlation and a review of the literature. Ann Diagn Pathol. 2026 Dec.85:152700. Pubmedid: 42580287.
• Eyre TA, Mohseninejad L, Barnieh L, Wang K, He Y, Yang K, Williams R, Shah BD. An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma. J Med Econ. 2026 Dec.29(1):1923-1932. Pubmedid: 42452801.
• Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Hodi FS, Li T, Yoder SJ, Streicher H, Hwu P, Sondak VK, Kirkwood JM, Wang X, Kanetsky PA. Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors. Melanoma Res. 2026 Oct.36(5):407-415. Pubmedid: 42647409.
• Perales MA, Dietrich J, Gust J, Santomasso B, Rejeski K, Hansen D, Shah NN, Berdeja J, Bishop M, Bleickardt E, Brudno J, Dahiya S, Frey N, Frigault MJ, Gardner R, Ghobadi A, Grupp S, Hamadani M, Jacobson C, Jain MD, Jain T, Komanduri KV, Kumar A, Lim S, Lin Y, Miao H, Neelapu S, Otegbeye F, Park JH, Pasquini M, Patel N, Plautz G, Verdun N, Lee DW, Maus MV, Locke FL. ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy. Transplant Cell Ther. 2026 Sep. Pubmedid: 42711241.
• Hoogland AI, Li X, Hu B, Irizarry-Arroyo N, Welniak T, Rodriguez Y, Jain MD, Oswald LB, Small BJ, Snider JT, Wade SW, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Pidala JA, Logue J, Booth-Jones M, Mirza AS, Huang J, Locke FL, Jim HSL. Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Support Care Cancer. 2026 Sep.34(10). Pubmedid: 42709238. Pmcid: PMC13553681.
• Lorch JH, Wong K, Tishler RB, Haddad RI, O'Neill A, Shin KY, Liu M, Hanna GJ, Chau NG, Rabinowits G, Schoenfeld JD, Margalit DN, Goguen L, Uppaluri R, Thomas T, Kacew A, McHugh P, Harris E, Austin K, Huang J, Mahmood U, Kochupurakkal BS, Sholl LM, Spangle JM. Phase 1 trial and biomarker analysis of Buparlisib with weekly Cisplatin and Radiotherapy in high risk locally advanced squamous cell cancer of the Head and Neck. Clin Cancer Res. 2026 Sep. Pubmedid: 42714839.
• Valcarcel B, Vasquez JF, Enriquez-Vera D, Beltran BE, Castro D, Runciman T, Idrobo H, Arrieta E, Arias O, Roa M, Peña C, Fiad L, Ramos JC, Sandoval-Sus J, Khan A, Sica A, Bell BN, Zhang Y, Leautaud V, Miranda ECM, Chiattone C, Malpica L. Outcomes of CHOP versus CHOEP/EPOCH in aggressive adult T-cell leukemia/lymphoma: an international cohort analysis. Haematologica. 2026 Sep. Pubmedid: 42719981.
• Bentebibel SE, McGrail DJ, Kochat V, Arslan E, Abdel-Wahab R, Pazdrak B, Murthy R, Tahon NHM, Cho SN, Duose DY, Wani K, Liu J, Haymaker C, Gomez JA, Sonnemann H, Katailiha AS, Nassif-Rausseo B, Rahim M, Li I, Mayer AT, Yang X, Hsu FJ, Zhang J, Johnson DH, Amaria RN, Glitza Oliva IC, Patel SP, Hwu P, Elsayes KM, Tawbi HA, Burks JK, Bernatchez C, Davies MA, Rai K, Lizee G, Ekmekcioglu S, Diab A. Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study. Cancer Discov. 2026 Sep.16(9):1780-1800. Pubmedid: 42013310. Pmcid: PMC13530994.
• Karapetyan L, Moser J, Ma BT, Otteni C, Cathcart E, Loo K, Jacoby J, Chau JK, Smithy JW, Nayee N, Pavlick AC, Tawashi A, Seshaadri A, Yi M, Finckenstein FG, Gastman B, Shoushtari AN. Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma. Transplant Cell Ther. 2026 Sep.32(9):1098-1110. Pubmedid: 42092582.
• Blumenberg V, Diorio C, Gauthier J, Agrusa JE, Dreyzin A, Hänel G, Espinoza-Gutarra MR, Geer M, Perales MA, Ramakrishna S, Jain MD, Gill S, Locke FL, Shouval R, Subklewe M, Komanduri KV, Chapuis AG, Paczesny S, Rejeski K, Shah NN. Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells. Transplant Cell Ther. 2026 Sep.32(9):1055.e1-1055.e23. Pubmedid: 42144191.
• Noble JD, Peixoto BC, Menges MA, Abraham-Miranda J, Savid-Frontera C, Sawyer W, Sorathia VD, Cuadrado Delgado LA, Corallo SA, Llanos JC, Merritt EC, De Avila G, Castaneda-Puglianini OA, Liu HD, Alsina M, Nishihori T, Shain KH, Siqueira Silva AS, Baz RC, Blue BJ, Grajales-Cruz AF, Hansen DK, Cleveland JL, Perna F, Lynch CC, Binning JM, Atkins RM, Song X, Locke FL, Freeman CL. Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. Blood. 2026 Sep.148(11):1409-1422. Pubmedid: 42275255.
• Yilmaz AS, Pepe A, Castelli JE, Sawyer WG, Dunne M. Hydrogel-based cellular drug delivery systems as living therapeutics: Micro/nanogel design, fabrication, and controlled release. J Control Release. 2026 Sep.397:115130. Pubmedid: 42341988.
• Seitter S, Mullinax JE. Invited Editorial about Article: "Salvage Metastasectomy after Adoptive Cell Transfer for Melanoma: Long-Term Updates" by Dinerman, Aaron et al. Ann Surg Oncol. 2026 Sep.33(9):7815-7816. Pubmedid: 42360643.
• Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik SA, Mathews J, Shaughnessy PJ, Mountjoy L, Dykes KC, Logan AC, Schwartz MS, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg RT, Tracy SI, Yalniz FF, Yaghmour G, Pullarkat VA, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I. Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood Adv. 2026 Sep.10(17):5821-5827. Pubmedid: 42349018. Pmcid: PMC13543946.
• Hamilton BK, Onstad L, Carpenter PA, Pidala J, Chen G, Cutler C, El Jurdi N, Farhadfar N, Juckett M, Kitko CL, Lee CJ, Lee SJ. Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial. Am J Hematol. 2026 Sep.101(9):2280-2287. Pubmedid: 42385358. Pmcid: PMC13428368.
• Lee SJ, Cutler C, Ma N, Randolph TW, Chen GL, Pidala J, Hamilton BK, Kitko CL, Arai S, El Jurdi N, Onstad L, Koyama M, Lee CJ, Paczesny S, Hill GR. Plasma proteins associated with chronic graft-versus-host disease organ involvement. JCI Insight. 2026 Sep.11(17). Pubmedid: 42518291. Pmcid: PMC13564087.
• Saeed H, Varela MM, Sahakian E, Naqvi M, Mo Q, Zhang L, Makanji R, Zhang Y, Dong N, Isenalumhe L, Gaballa S, Chavez J, Shah B, Bello C, Sokol L, Pinilla-Ibarz J. A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma. Hematol Oncol. 2026 Sep.44(5):e70235. Pubmedid: 42545812. Pmcid: PMC13431344.
• El-Atoum M, Chen GL, Segal BH, Bonnewell JP, Almyroudis NG. Epidemiology and Species Distribution of Candida Bloodstream Infections in a Comprehensive Cancer Center, 2008-2023. Mycopathologia. 2026 Sep.191(5). Pubmedid: 42684546. Pmcid: PMC13538229.
• Karapetyan L, Jain MD. Beyond Hospital Discharge: Defining Outpatient Care After Tumor-Infiltrating Lymphocyte Therapy. JCO Oncol Pract. 2026 Sep.OP2601014. Pubmedid: 42696682.
• Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. Ann Surg Oncol. 2026 Sep. Pubmedid: 42693375.
• Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial. Ann Surg Oncol. 2026 Sep. Pubmedid: 42700336.
• Sobierajska E, Medina CB. The cost of persistence: MEK and metabolic demand. Immunity. 2026 Aug.59(8):2058-2060. Pubmedid: 42580317.
• Silvane L, Zelenka T, Talada DP, Cismasiu VB, Islam S, Singh RP, Ngove Z, Chakraborty S, Hall MS, Blauvelt JL, Eksioglu E, Manrique SZ, Johnson JO, Obermayer AN, Alfaro A, Huang W, Sarnaik A, Tarhini AA, Mullinax JE, George E, Hwu P, Davila E, Conejo-Garcia JR, Bryceson YT, Chen DT, Shaw TI, Pilon-Thomas S, Avram D. BCL11B targeting in tumor CD8 + T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness and cytotoxicity. bioRxiv. 2026 Aug. Pubmedid: 42601873. Pmcid: PMC13470569.
• Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Peggs KS, Roddie C. Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia". Haematologica. 2026 Aug.111(8):2873. Pubmedid: 42609184. Pmcid: PMC13482257.
• Pidala J, Choe H, Alousi A, Kitko CL, Onstad L, Mehta R, Desatnik G, Wu QV, Lee SJ. Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease. Transplant Cell Ther. 2026 Aug. Pubmedid: 42624289.
• Oliai CH, Gandhi A, Hoeg RT, Muffly L, Srour SA, Mehta RS, Waller EK, Lowsky R, Patel SS, Dholaria B, Pantin J, Salhotra A, McGuirk JP, Gomez-Arteaga A, Faramand R, Tamari R, Holter-Chakrabarty J, Hamilton BK, Jimenez AMJ, Murray J, Killian MS, Pavlova A, Fernhoff NB, McClellan JS, Abedi M, Negrin RS, Meyer EH. Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients. Transplant Cell Ther. 2026 Aug. Pubmedid: 42628650.
• Martinez-Planes E, Ramello MC, Fontela MG, Shokri MR, Tran T, Darville L, Koomen J, Kim Y, Abate-Daga D. C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells. Mol Ther. 2026 Aug. Pubmedid: 42642932.
• Bashey A, Lee SJ, Devine SM, Shaw BE, Dehn JG, Pidala JA, Hogan WJ. Umbilical Cord Blood Donor Outcomes in BMTCTN1702. Blood Adv. 2026 Aug. Pubmedid: 42664501.
• Le THN, Nguyen QT, Kim Y, Balkaran V, Bhathivi T, Pilon-Thomas S, Markowitz J. pAc/Emm55 increases anti-melanoma immunity via TLR2 signaling in dendritic cells and improves checkpoint blockade efficacy. Front Immunol. 2026 Aug.17:1863894. Pubmedid: 42688222. Pmcid: PMC13534055.
• Lindenbergh PL, Rajasekhar VK, Linkov I, Mansilla-Soto J, Hanina SA, Sadelain M. Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells. Front Immunol. 2026 Aug.17:1852493. Pubmedid: 42718816. Pmcid: PMC13553483.
• Henning J, Venkat S, Kumar P, El-Haddad G, Brohl A, Ribeiro M, Mhaskar R, Naghavi A, Druta M, Kis B. Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma. Abdom Radiol (NY). 2026 Aug.51(8):4150-4157. Pubmedid: 41545559.
• Shields MD, Minton KG, Ozakinci H, Zhou T, Terry OC, Kumar P, Akel R, Girard L, Minna JD, Boyle TA, Koomen JM, Shafique M. ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin. Mol Cancer Ther. 2026 Aug.25(8):1393-1407. Pubmedid: 41582485.
• Xu X, Liu X, Jarajapu V, Neelature Sriramareddy S, Konecny F, Posorske B, Dollar JJ, Liu X, Jasani N, Wang K, Mecozzi N, Soto-Vargas Z, Ochoa-Rios SL, Murikipudi H, Phan N, Chadourne M, Kuznetsoff JN, Sinard J, Bennett RL, Licht JD, Smalley KSM, Harbour JW, Yu X, Karreth FA. A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer Res. 2026 Aug.86(15):3666-3686. Pubmedid: 41661679. Pmcid: PMC12974268.
• Hernandez DA, Andreozzi JM, Decker SM, Hernandez A, Adkins SD, Ahmed KA, Diaz R, Mills MN, Washington IR. Daily Cherenkov Imaging to Monitor for Unintended Field Overlap During Bilateral Breast Radiation Therapy. Pract Radiat Oncol. 2026 Aug.16(5):e444-e455. Pubmedid: 41864282.
• Baumrucker CC, Harris N, Aiello P, Whiting J, Sun W, Soliman H, Han H, Costa R, Czerniecki BJ, Lee MC. Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. J Surg Oncol. 2026 Aug.134(2):220-225. Pubmedid: 42130226. Pmcid: PMC13427119.
• Muffly L, Frey NV, Roloff GW, Park JH, Dholaria B, Advani AS, Bachanova V, Cassaday RD, Daunov M, Dykes KC, Irizarry Gatell V, Grunwald MR, Hilal T, Hill LC, Jamy O, Kota VK, Kumaran M, Lin C, Logan AC, Luskin MR, O'Dwyer KM, Oliai C, Oluwole OO, Sasine JP, Schwartz MS, Solh MM, Stock W, Tsai SB, Ulrickson ML, Vasu S, Wang ES, Yalniz FF, Strickland SA, Leonard JT, Shah BD, Aldoss I. Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026 Aug.148(6):657-668. Pubmedid: 42154904.
• Yan F, Cruz-Correa M, Specht J, Wang EW, Lu J, Soliman H, Jackson-Fisher A, Tang SY, Jiang S, Le Corre C, Li M, Sommerhalder D. A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer. Invest New Drugs. 2026 Aug.44(4):305-316. Pubmedid: 42171881. Pmcid: PMC13486042.
• Gaál Z, Meehan C, Yilmaz M, Ujhazi B, Suhet P, Miller R, Dasso J, Nomula K, Franson B, Toth M, Potts E, Gokbak MN, Gordon S, Ellison M, Cruz R, Asante-Korang A, Cassani FA, Betensky M, Butte M, Cooper MA, Cockrell E, Galligan A, Glaum M, Grimbacher B, Fliegauf M, Meyer A, Milojevic D, Minor M, Mendez EM, Metts J, Nieves D, Ong MS, Oshrine BR, Patel P, Prpich J, Purser J, Ramirez A, Rosenberg D, Schlefman A, Shaker A, Shah S, Shah B, Santiago L, Obzut D, Sriaroon P, Thatayatikom A, Weis E, Mayer J, Farmer JR, Csomos K, Eslin D, Ayala I, Westermann-Clark E, Walter JE. Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia. Pediatr Blood Cancer. 2026 Aug.73(8):e70367. Pubmedid: 42226607.
• Bashey A, Logan BR, Hill LC, Symons HJ, Farhadfar N, Grunwald MR, Pidala JA, Dehn JG, Brunstein C, Arai S, Leifer E, He N, Shaw BE, Juckett MB, Devine SM, Uberti J, Westervelt P, Srour SA, Pusic I, Vasu S, Hayes-Lattin B, Ciurea SO, Horowitz MM, Lee SJ, Hogan WJ. Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial. Blood Adv. 2026 Aug.10(16):5543-5552. Pubmedid: 42263667. Pmcid: PMC13482518.
• Dacoregio MI, Rego Castro CED, Mamede I, Rodrigues CG, Thimotheo Batista JP, Michelon I, Ribeiro PZ, Oliveira Junior JR, Bonadio RC, Vilbert M, Barros Costa RL. Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis. Breast. 2026 Aug.88:104821. Pubmedid: 42372581. Pmcid: PMC13330674.
• Basta A, Lien K, Ni G, Sun W, Whiting J, Armitage M, Soyano AE, Armaghani A, Loftus L, O'Connor T, Dvir K, Han HS, Soliman H, Czerniecki BJ, Costa RLB. A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer. Clin Breast Cancer. 2026 Aug.26(8):7-13. Pubmedid: 42418955.
• Mandal G, Biswas S, Anadon CM, Tamuli B, Chaurio RA, Lopez-Bailon LU, Plappert N, Carrion-Estrada D, Mine JA, Lai CH, Moreno AP, Johnson J, Moran-Segura CM, Fang B, Marchion D, Chaudhary N, Terry KL, Sasamoto N, Townsend MK, O'Brien J, Antonia SJ, Tworoger SS, Yu X, Rodriguez PC, Conejo-Garcia JR. Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression. iScience. 2026 Aug.29(8):116757. Pubmedid: 42472098. Pmcid: PMC13380442.
• Karapetyan L, Xu J, Ward K, Kalos D, Schachner B, Ali J, Song X, Kuriakose J, Hall MS, Chau J, Cox CA, Al-Bzour AN, Falahat R, Perez MC, Mullinax JE, Zager JS, Gonzalez R, Sondak VK, Tsai KY, Messina JL, Moran-Segura C, Lopez-Blanco N, Alleyne AE, Nguyen JV, Schell MJ, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Hwu P, Mulé JJ, Sarnaik AA, Beatty MS, Pilon-Thomas S. Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma. Med (N Y). 2026 Aug.7(8):101231. Pubmedid: 42526429. Pmcid: PMC13425943.
• Tyson MD, Nam JK, Joshi SS, Uchio EM, Jung SI, Bivalacqua TJ, Steinberg GD, Shore ND, Burke JM, Kitamura H, Tran B, Li R. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. Lancet Oncol. 2026 Aug.27(8):983-993. Pubmedid: 42508433.
• Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MC, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. Ann Surg Oncol. 2026 Aug. Pubmedid: 42545411.
• Movva S, Allgood V, Chugh R, Davis LE, Bailey HH, Milhem M, Monga V, Attia S, Mangla A, Bruns I, Kuttschreuter L, Bouyoucef-Cherchalli D, Wei C, Lin GHY, Zhang H, Pomerance I, Druta M, Chawla S. A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma. Brit J Cancer. 2026 Aug. Pubmedid: 42552364.
• Hensley PJ, Teoh JYC, Li R, Gupta S, Bukavina L, Mouw KW, Lobo N, Maiorano BA, Tan WS, Agarwal P, Al-Ahmadie HA, Bivalacqua TJ, Cheng L, Flaig TW, Guo CC, Horowitz A, Kassouf W, Kates MR, Konety BR, Kukreja JB, Lotan Y, McConkey DJ, Mertens LS, Mir MC, Moschini M, Necchi A, Oualla K, Packiam VT, Schmidt B, Buckley RJ, Kamat AM. Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group. Nat Rev Urol. 2026 Aug. Pubmedid: 42557383.
• Lotan Y, Margulis V, Woldu S, Allison D, Kim JK, Bukavina L, Chang SS, Krishna V, Kaul G, Neema A, Zhang H, Royce TJ, Krishna V, Joshi A, Kamat AM, Li R, Hensley PJ. Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer. Urol Oncol. 2026 Aug. Pubmedid: 42575840. Pmcid: PMC13527431.
• Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul.395(4):338-348. Pubmedid: 42485627.
• Seo M, Hatoum F, Swank J, Isenalumhe L, Koblitz A, Pena A, Davis D, Woerz J, Kareem SS, Buffington H, Brohl AS, Metts J, Druta M, Schneider A, Chahoud J. Evaluation of the Feasibility and Safety of Ifosfamide-Based Chemotherapy Regimens for Sarcomas in the Outpatient Setting. JCO Oncol Pract. 2026 Jul.OP2501196. Pubmedid: 42407003.
• Hosoya H, Velayati A, Dima D, Jensen A, Portuguese AJ, Hovanky V, Mikkilineni L, Peres LC, Grajales-Cruz AF, Homsy S, Rana MS, Cancilla J, Patil S, Sahaf B, Latchford T, Freeman CL, Scott BJ, Song KW, Castaneda-Puglianini OA, Khan H, Dahiya S, Locke FL, Mackall CL, Miklos DB, Banerjee R, Hansen DK, Alsina M, Sidana S. Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma. Blood. 2026 Jul. Pubmedid: 42418682.
• Simonovich JA, Clark RA, Kwiatkowski AJ, Fuchs MJ, Viso ME, Lu C, Macias SL, Pinto I, Shrestha AP, Ngo TB, Duarte S, He Y, Hu Q, Lu G, Hartman JB, Su G, Scali ST, Berceli SA, Sharma AK, Upchurch GR, Islam S, Wanchoo A, Hudalla GA, Robinson ST, Zarrinpar A, Avram D, Keselowsky BG. Circulating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence. Proc Natl Acad Sci U S A. 2026 Jul.123(28):e2602536123. Pubmedid: 42418487. Pmcid: PMC13367878.
• Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Leitch AM, Lyons J, McCloskey S, McShane M, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Speers C, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Ne. 2026 Jul.24(7). Pubmedid: 42425164.
• Bruno S, Knight AD, Layding CJ, Wang H, Storkus WJ, Karapetyan L, Kirkwood JM. Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma. Melanoma Res. 2026 Jul. Pubmedid: 42421561.
• Vincelette ND, Mo Q, Cheng CH, Park J, Kuykendall AT, Zhang L, Moon J, Razabdouski TN, Eksioglu EA, Lledo FM, Papenhausen PR, Xie Z, Chan O, Sallman DA, Pinilla-Ibarz J, Murphy DJ, Komrokji RS, Cleveland JL, Yu X, Yun S. Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality. medRxiv. 2026 Jul. Pubmedid: 42428085. Pmcid: PMC13345432.
• Mora-Garijo B, Rahman S, Xu H, Chatzkel J, Grass GD, Spiess PE, Li R. Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications. Cancers (Basel). 2026 Jul.18(13). Pubmedid: 42449716. Pmcid: PMC13359999.
• Topp MS, Shah BD, Jabbour E, Park JH, Shaughnessy P, Logan AC, Sandhu KS, Abedi M, Bishop MR, DeAngelo DJ, Yin X, Davi R, Hodby K, Malladi R, Brugger W, Shang J, Roddie C, Kantarjian HM. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026 Jul. Pubmedid: 42469475.
• Saha A, Whiting J, Mohty R, Flores K, Kim J, Nishihori T, Chavez J, Gaballa S, Khimani F, Liu H, Shah B, Dam M, Jaffer M, Mokhtari S, Ghalehsari N, Elmariah H, Bachmeier C, Guevara JA, Jim H, Mirza S, Segal BH, Hansen DK, Bejanyan N, Perna F, Faramand R, Jain M, Locke F, Lazaryan A. A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma. Bone Marrow Transplant. 2026 Jul. Pubmedid: 42469394.
• Pidala JA, Kim J, Laborde J, Knott S, Mogili K, Zinn J, Monroe AR, Faramand R, Ramlal R, Khimani F, Hansen DK, Torres Luna NE, Jain MD, Perez LE, Mishra A, Ghalehsari N, Castaneda-Puglianini OA, Alsina M, Perna F, Nieder M, Mirza AS, Liu HD, Nishihori T, Ali A, Chellapandian D, Locke FL, Bejanyan N, Anasetti C, Lazaryan A. Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis. Blood Adv. 2026 Jul. Pubmedid: 42480215.
• Pidala JA, Hamilton BK, Chen GL, Onstad L, Pavletic SZ, Carpenter PA, Lee CJ, Kitko CL, Farhadfar N, Hall AM, Mays JW, Lee SJ. Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development. Blood Adv. 2026 Jul. Pubmedid: 42486676.
• Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MC, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Van't Veer LJ, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial. Ann Surg Oncol. 2026 Jul. Pubmedid: 42536241.
• Rossetti RAM, Beatty MS, Cianne J, Ali JR, Harris K, Ramadan A, Grant M, Planes EM, Aurelio J, Karapetyan L, Creelan B, Pilon-Thomas S, Hwu P, Luca VC, Abate-Daga D. Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion. bioRxiv. 2026 Jul. Pubmedid: 42538952. Pmcid: PMC13419458.
• Basharat A, Mannan MS, Shabbir MR, Khan MW, Basit T, Park R, Chadha J, Shahzad M. Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2026 Jul.24(6):102625. Pubmedid: 42556088.
• Jain N, Shi Y, May C, Mitra S, Bucher P, Dobrin A, Zhao Z, Hanina S, Rajasekhar VK, Yao Y, Mansilla-Soto J, Leibold J, Leslie CS, Sánchez-Rivera FJ, Feucht J, Sadelain M. Integrated Chronic In Vivo and In Vitro Screens Uncover NFIL3 as a Driver of T-cell Dysfunction. Cancer Discov. 2026 Jul.16(7):1456-1471. Pubmedid: 41747243.
• McCrary MR, Chen PL, Messina JL. Sweat Gland Carcinoma With Neuroendocrine Differentiation (SCAND) Harboring a Novel GATA3 Frameshift Extension Mutation: A Case Study With Protein Structural Modeling. J Cutan Pathol. 2026 Jul.53(7):590-595. Pubmedid: 41844250.
• Wolff D, Solano C, Michonneau D, Bonifazi F, Mehra V, Hall K, Lazaryan A, Lee CJ, Logan AC, van der Laan M, Gruber S, Kabadi S, Khan I, Nicholls C, Rota L, Nikai E, Ponomareva E, Koumas A, Waller EK. Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease. Transplant Cell Ther. 2026 Jul.32(7):905.e1-905.e13. Pubmedid: 41895695.
• Ali A, Ozdemirli M, Hamilton MP, Jain MD. Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders. Nat Rev Clin Oncol. 2026 Jul.23(7):520-538. Pubmedid: 41986503.
• Suzuki S, Kandar B, Ting C, Deraska P, Chen TA, Giridharan T, Khan ANH, Attwood K, Yu H, Catalfamo K, Singh PK, Bushey RT, Gottlin EB, Campa MJ, Patz EF, Ajona D, Pio R, Segal BH, Yau EH. Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. Cancer Immunol Res. 2026 Jul.14(7):1172-1185. Pubmedid: 42048614. Pmcid: PMC13348722.
• Oswald LB, Li X, Gudenkauf LM, De Avila G, Scheiber-Camoretti D, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker NH, Carson TL, Vinci CE, Baz RC, Shain KH, Blue B, Grajales-Cruz A, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini O, Nishihori T, Liu H, Locke FL, Jim HSL, Peres LC, Hansen DK. Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. Bone Marrow Transplant. 2026 Jul.61(7):864-872. Pubmedid: 42115674. Pmcid: PMC13349860.
• Aljawai YM, Nawas MT, McCurdy SR, Kanakry CG, Kanakry JA, Rimando JC, Saultz JN, Al-Juhaishi T, Lazaryan A, Milano F, Mehta RS. Absolute risk trade-offs of donor age, sex, and graft source in PTCy-based transplantation. Blood Adv. 2026 Jul.10(14):4884-4888. Pubmedid: 42160761. Pmcid: PMC13382315.
• Navarre S, Ishibashi MN, Nair A, Reyes-Torres I, Belabed M, Halasz L, Park MD, Mattiuz R, Ounadjela M, Gunset G, Mansilla-Soto J, Feucht J, Cabriolu A, Le Berichel J, Birbrair A, Eyquem J, Brown BD, Merad M, Sadelain M, Ahmed J. Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases. Nat Cancer. 2026 Jul.7(7):1104-1120. Pubmedid: 42174275. Pmcid: PMC13400301.
• Hahn T, Zhao Q, Miller EG, Elder P, Langenberg L, Luebbering N, Abdullah S, Neidemire-Colley L, Holtan SG, Cataland SR, Ranganathan P, Davies SM, Bejanyan N, Vasu S. TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study. Blood Adv. 2026 Jul.10(14):5076-5086. Pubmedid: 42234937. Pmcid: PMC13400942.
• Roddie C, Day W, Raymond M, Cluxton D, Caulfield J, Dainton-Smith H, McElwee B, Hu Y, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Yallop D, Barba P, Guerreiro M, Yared JA, Hodby K, Shah BD, Brugger W, Lao-Sirieix P, Bishop MR, DeAngelo DJ, Jabbour E, Park JH. CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Res Commun. 2026 Jul.6(7):1681-1692. Pubmedid: 42241689. Pmcid: PMC13370329.
• de Jong D, McGale JP, Robinson TJ, Liao MJ, Das JP, Major A, Capaccione KM, Ladbury C, Mansilla-Soto J, Ma H, Al Feghali KA, Goy AH, Lopci E, Reshef R, Schwartz LH, Houot R, Dercle L. CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment. J Nucl Med. 2026 Jul.67(7):1021-1031. Pubmedid: 42386374.
• Zhang M, Rausseo BN, Jiang P, Bontekoe E, Alves AM, Slone J, Rinsurongkawong W, Rinsurongkawong V, Patel A, Lewis J, Davies M, Hwu P, Lee J, Wistuba I, Vaporciyan A, Deniger D, Lizee G, Yee C, Kavraki L, Gibbons D, Tran H, Zhang J, Heymach J, Reuben A. Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinations. Res Sq. 2026 Jun. Pubmedid: 42370266. Pmcid: PMC13308340.
• Kim K, Hunzeker Z, Sun X, Sun R, Voorhees T, Youssef Y, Epperla N, De Castro M, Ow K, Santiago M, Varghese J, Ayers A, Ramdial J, Hosing C, Kebriaei P, Shpall E, Jain M, Chavez J, Locke FL, Neelapu SS, Ahmed S, Strati P. Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART. Blood Immunol Cell Ther. 2026 Jun.2(2). Pubmedid: 42416925. Pmcid: PMC13340592.
• Nguyen QT, Kim Y, Le THN, Garg S, Balkaran V, Bhathivi T, Chamizo A, Dukes CW, Ward K, Brohl AS, Karapetyan L, Khushalani NI, Eroglu Z, Tarhini AA, Mulé JJ, Markowitz J. iNOS is a key mediator of anti-PD-1 melanoma therapy response. Front Immunol. 2026 Jun.17:1837275. Pubmedid: 42440610. Pmcid: PMC13333588.
• Chakraborty P, Chatterjee S, Kassir MF, Wofford W, Choi S, Oleinik N, Saatci O, Darawshi O, Das S, Oberhoeltzer N, Gautam A, Mills S, DeMass R, Hedley Z, Liu Y, Parikh RY, Paul S, Seal S, Smith CD, Lilly MB, Gangaraju VK, Peterson Y, Mehrotra M, Hill E, Sahin O, Leitinger N, Rodriguez PC, Ogretmen B, Mehrotra S. Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis. Nat Commun. 2026 Jun.17(1). Pubmedid: 42230631. Pmcid: PMC13392128.
• Guerriero JL, Merad M, Ginhoux F, Ostuni R, de Visser KE, Pittet MJ, Brandau S, Merghoub T, Egeblad M, Umansky V, van Vlerken-Ysla L, Marron TU, Coussens LM, Zarif JC, Ruffell B, Barry ST, Varner JA, Gabrilovich DI. Expert opinion on burning questions in cancer myeloid cell biology. J Immunother Cancer. 2026 Jun.14(6). Pubmedid: 42236113. Pmcid: PMC13239654.
• Canevarolo RR, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, DeAvila D, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst L, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer J, Dalton W, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma. Cancer Res. 2026 Jun. Pubmedid: 42233980.
• Tagal V, Li T, Kumar R, Shrestha P, Yu X, Miroshnychenko D, Olumoyin K, Marusyk A, Davies M, Maudsley S, El-Naqa I, Gomes AP, Duckett DR, Han HS, Andor N. Ploidy shapes gemcitabine response through altered potency and delayed cell death. bioRxiv. 2026 Jun. Pubmedid: 42282758. Pmcid: PMC13251900.
• Churchman M, Lu X, McKean D, Radmacher M, Zhang Q, Rounbehler R, Tan A, Shaw T, Obermayer A, Grass G, Spakowicz D, Tarhini A, Shain K, Canevarolo R, Meads M, Silva AS, Sudalagunta PR, Manley B, Huntsman S, Collyar D, Kolesar J, Evers BM, Single N, Edge S, Johnson C, Weiner G, McCarter M, Borges V, Horne L, Lillard J, Mudaranthakam D, White J, Libutti S, Ganesan S, Riedlinger G, Loughran T, Halme D, Johns M, Arciero C, Salhia B, Naqash AR, Shriver C, Lee K, Schneider B, Nix D, Fillmore G, Colman H, Ulrich C, Springer B, Pollock R, Vucic E, Sherman J, Jain A, Dalton W, Agius P, Siegel E. The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology. Res Sq. 2026 Jun. Pubmedid: 42281974. Pmcid: PMC13252564.
• Parker NH, Kim J, Bean M, De Vera MT, Carmella R, Duca A, Corallo S, Delgado LC, Merritt E, McCoy J, Brushwood A, Franca M, Hansen DK, Castaneda-Puglianini O, Lazaryan A, Chavez J, Nishihori T, Shah B, Faramand R, Mirza AS, Akhtar O, Peres LC, Figura NB, Jhaveri K, Oswald LB, Jim HSL, Locke FL, Jain M, Freeman CL. Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes. Transplant Cell Ther. 2026 Jun. Pubmedid: 42315024.
• Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Stephen Hodi F, Li T, Yoder SJ, Streicher H, Sondak VK, Kirkwood JM, Wang X, Kanetsky PA. Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma. J Immunother Cancer. 2026 Jun.14(6). Pubmedid: 42320988. Pmcid: PMC13289257.
• Blue B, Lake P, Pidala J, Jim H, Locke FL, Vadaparampil S. Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. J Cancer Educ. 2026 Jun. Pubmedid: 42319704.
• Pidala JA, Cieri N, Schell MJ, Song X, Shao Y, Cao B, Du D, Thapa R, Betts BC, Janssen W, Cubitt C, Yoder SJ, O'Leary MF, Beato F, Veerapathran A, Menges MA, Burton M, Bejanyan N, Castaneda-Puglianini OA, Elmariah H, Faramand RG, Fernandez HF, Hansen DK, Jain MD, Khimani F, Lazaryan A, Liu HD, Locke FL, Mirza AS, Mishra A, Nieder M, Nishihori T, Ochoa L, Perez LE, Perna F, Ramlal R, Torres NE, Anasetti C. Expanded antigen-specific donor regulatory T cells for GVHD prevention. Blood. 2026 Jun. Pubmedid: 42322116.
• Othus M, Truong TG, Sharon E, Kendra K, Grossmann K, Buchbinder E, Khushalani NI, Eroglu Z, Chandra S, Doolittle GC, Kirkwood JM, Ikeguchi A, Mihalcioiu C, Cowey CL, Reddy SA, Johnson DB, Taylor M, Sondak VK, Ribas A, Patel SP. Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy. JCO Oncol Pract. 2026 Jun.OP2501413. Pubmedid: 42335437. Pmcid: PMC13293282.
• Aydogdu C, Bukavina L, Cheng L, Al-Ahmadie HA, Alhalabi O, Brown JR, Lopez-Beltran A, Grivas P, Hwang C, Grass GD, Kamat AM, Chatzkel J, Mian O, Necchi A, Ross J, Apolo AB, Spiess PE, Li R. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. 2026 Jun. Pubmedid: 42362411. Pmcid: PMC13336308.
• Faramand RG, Zhang A, Roloff GW, Aldoss I, Advani AS, Battiwalla M, Boccucci J, Byrd K, Cassaday RD, Connor M, Dykes KC, Hilal T, Kopmar NE, Kota VK, Lee CJ, Leonard JT, Lill GR, Lin C, Logan AC, Majhail NS, Malik SA, McCauley R, Moore J, Mountjoy L, O'Connor T, O'Dwyer KM, Bobillo SO, Oliai CH, Othman T, Ramakrishnan A, Sandhu K, Schwartz M, Shaughnessy P, Srinagesh HK, Sutherland KC, Tan V, Tsai SB, Ulrickson M, Wang ES, Yaghmour G, Frey NV, Shah BD, Muffly LS. Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblasti. Transplant Cell Ther. 2026 Jun. Pubmedid: 42364734.
• Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]. Transplant Cell Ther. 2026 Jun.32(6):765-766. Pubmedid: 41067707. Pmcid: PMC12677140.
• Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C. Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026 Jun.111(6):1999-2010. Pubmedid: 41504229. Pmcid: PMC13231109.
• Markova A, Lee SJ, Modi B, Baumrin E, Rosenstein RK, Tkaczyk ER, Lehman JS, Inamoto Y, Carpenter PA, Schultz KR, Pidala JA, Martin P, Pusic I, Goklemez S, Stockmann C, Pinal-Fernandez I, Paczesny S, Harris A, Ponce DM, Holtzman NG, Jurdi NE, Pavletic SZ, Cowen EW. Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force. Transplant Cell Ther. 2026 Jun.32(6):644.e1-644.e19. Pubmedid: 41539488. Pmcid: PMC12858292.
• Pidala J, Logan B, Lee SJ, Shaw BE, Devine S, Ciurea SO, Horowitz M, He N, Pusic I, Srour SA, Arai S, Juckett M, Uberti J, Hill L, Vasu S, Hogan WJ, Hayes-Lattin B, Westervelt P, Bashey A, Farhadfar N, Grunwald MR, Leifer E, Symons H, Saad A, Vogel J, Erickson C, Buck K, Dehn JG. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial. Transplant Cell Ther. 2026 Jun.32(6):678-688. Pubmedid: 41547399. Pmcid: PMC13086071.
• Gleber-Netto FO, Silverman D, Xie T, Akhter S, Vaughn NR, Adebayo A, Debnath KC, Naara S, Islam S, Knutsen E, Ashkin EL, Anfossi S, Leahey S, Hwu P, Talbot S, Sloan EK, Saddawi-Konefka R, Rangel R, Myers JN, Calin GA, Amit M. β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma. Adv Sci (Weinh). 2026 Jun.13(35):e16859. Pubmedid: 41665072. Pmcid: PMC13292172.
• Gupta S, Li R, Hensley PJ, Daneshmand S, Faltas BM, Grivas P, Lobo N, Mir MC, Meeks JJ, Mouw KW, Moschini M, Necchi A, Oualla K, Pohar KS, Rosenberg JE, Schmidt B, Siefker-Radtke AO, Steinberg GD, Stenzl A, Buckley RJ, Kamat AM. Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026 Jun.89(6):500-511. Pubmedid: 41724648.
• Kamat AM, Hensley PJ, Maiorano BA, Li R, Psutka SP, Mouw KW, Horowitz A, Gupta S, Necchi A. Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non-Muscle-Invasive Bladder Cancer Progress or Overreach?. J Clin Oncol. 2026 Jun.44(16):1478-1482. Pubmedid: 41771028.
• Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, Bajor DL, Mukherjee S, Saltzman J, Maguire O, Minderman H, Chatley S, Tarquini ML, Whitworth A, Jurcevic J, Hsiao HH, Knudsen ES, Muhitch JB, Abrams SI, Kalinski P, Segal BH, Bakin A, Yuan G, Wang C, Attwood K, Iyer R, Boland PM. TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. Int J Cancer. 2026 Jun.158(12):3300-3311. Pubmedid: 41793309. Pmcid: PMC13019156.
• Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Hodi FS, Li T, Monteiro AN, Streicher H, Sondak VK, Wang X, Kirkwood JM, Kanetsky PA. Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanoma. Melanoma Res. 2026 Jun.36(3):189-196. Pubmedid: 41812038. Pmcid: PMC13254891.
• Bontekoe E, Zhang M, Jiang P, Montoya A, Shulga Y, Slone JK, Paul E, Polera C, Forward S, Nassif Rausseo B, Assita ER, Xing C, Molkentine DP, Morris BB, Polic I, Roszik J, Salgado R, Vaishnavi A, Deniger D, Tran HT, Gibbons DL, Vaporciyan A, Gillison ML, Wistuba II, Kavraki LE, Zhang J, Lizee G, Yee C, Hwu P, Kwok S, Jaeger AM, Heymach JV, Reuben A. FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer. Cancer Immunol Res. 2026 Jun.14(6):958-973. Pubmedid: 41854516. Pmcid: PMC13119620.
• Ghali H, Al-Bzour AN, Boby A, Aflatooni S, DePalo DK, Dugan MM, Coughlin E, Mhaskar R, Tsai K, Zager JS, Sondak VK, Premi S, Storkus WJ, Messina JL, Karapetyan L. Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma. Am J Dermatopathol. 2026 Jun.48(6):439-448. Pubmedid: 41861255.
• Rees MJ, Cassano RC, Tan M, Zolotov E, Sidana S, Dima D, Kort J, Afrough A, Gaballa M, Pasvolsky O, Mikkilineni L, Khouri J, Raza S, Zanwar SS, Ferreri CJ, Kumar S, Khan AM, Atrash S, Portuguese AJ, Rana MS, Banerjee R, Freeman C, Blue B, Patel KK, Anderson LD, Puglianini OC, Shune LO, Biran N, Hansen DK, Lin Y. The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma. Am J Hematol. 2026 Jun.101(6):1314-1319. Pubmedid: 41862775.
• Blansfield R, Raman JD, Hensley P, Matin SF, Ungerer G, Potretzke AM, Margulis V, Singla N, Coleman J, Li R, Spiess PE, Clark R. Diagnostic dilemmas for upper-tract urothelial carcinoma (UTUC)-grade discordance between endoscopic biopsy and final surgical pathology. Urol Oncol. 2026 Jun.44(6):113-118. Pubmedid: 41904095.
• Ramlal R, Kim J, Thompson Z, Ochoa-Bayona L, Mishra A, Nishihori T, Perez L, Bejanyan N, Castaneda Puglianini O, Faramand R, Mirza S, Khimani F, Lazaryan A, Hansen D, Locke F, Artz A, Sorror M, Pidala J. Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT). Bone Marrow Transplant. 2026 Jun.61(6):702-704. Pubmedid: 41951840.
• Ravishankar A, Ramamoorthi G, Weiss T, Le Rhun E, Czerniecki BJ, Sundar R. Breaking the Immune Sanctuary: Targeting Metastatic Niches. Am Soc Clin Oncol Educ Book. 2026 Jun.46(3):e517520. Pubmedid: 42208002.
• Timofeeva N, Herrera B, Fujiwara H, Asami T, Endo H, Hatakeyama M, Nakajima F, Ohmoto H, Nishioka Y, Miyamoto K, Arimura A, Tantawy SI, Pinilla-Ibarz J, Coombs CC, Jain N, Sawa M, Gandhi V. Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. Blood Cancer J. 2026 May.16(1). Pubmedid: 42098067.
• Onimus A, Celias D, Chang S, Davis J, Mandula J, Li J, Gardner A, Hänggi K, Osunmakinde O, Soliman H, Shaw TI, Rodriguez PC, Ruffell B. Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion. Cell Rep Med. 2026 May.7(5):102788. Pubmedid: 42097146. Pmcid: PMC13198304.
• Vera O, Martinez M, Soto-Vargas Z, Wang K, Xu X, Mecozzi N, Murikipudi H, Ruiz-Buceta S, Chadourne M, Posorske B, Angarita A, Bok I, Ulloa Arrieta JD, Liu Q, Kim Y, Messina JL, Tsai KY, Major MB, Lau EK, Yu X, Ibanez de Caceres I, Karreth FA. A MAFG~MITF complex drives melanoma phenotype switching and progression. Nat Commun. 2026 May. Pubmedid: 42168173.
• Fisher J, Wu Y, Abate-Daga D, Barisa M, Lamb L. Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies. Nat Commun. 2026 May.17(1). Pubmedid: 42173864. Pmcid: PMC13280018.
• Shah B, Xue M, Furnback W, Esselman K, Chuang PY, Yang K. Real-World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States. Hematol Oncol. 2026 May.44(3):e70201. Pubmedid: 42176276.
• Johnson JS, Miller JW, Hatoum F, Schell MJ, Yu X, Roman Souza G, Mizelle S, Gullapalli K, Fazili A, Jain R, Chatzkel J, Cen L, Dhillon J, Cubitt C, Yao J, Whiting J, Li J, Swank J, Jameel G, Zhang J, Wang X, Spiess PE, Fishman M, Chahoud J. Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. Nat Commun. 2026 May.17(1). Pubmedid: 42185255.
• Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F. Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis. Haematologica. 2026 May. Pubmedid: 42206435.
• Blue B, Lake P, Pidala J, Jim H, Locke FL, Vadaparampil S. Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. J Cancer Educ. 2026 May. Pubmedid: 42217135.
• Ahmed KA, Quick AM, Chon HS, Chern JY, Bixel K, Kim Y, Li J, Montejo ME, Dowell RA, Kim S, Fernandez DC, Lam CA, Hakam A, Rosa M, Shafique M, Shahzad MM, Wenham RM. Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study. Int J Radiat Oncol Biol Phys. 2026 May.125(1):298-305. Pubmedid: 40379142. Pmcid: PMC12699517.
• Potez M, Jazayeri SB, Guske C, Miller J, Ali J, Carter M, Khambati F, Dhillon J, Sexton W, Zemp L, Manley B, Souza GR, Spiess PE, Beatty M, Pilon-Thomas S, Chahoud J. Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non-clear-cell Renal Cell Carcinoma. Eur Urol. 2026 May.89(5):469-471. Pubmedid: 40962596.
• Ghobadi A, Anagnostou T, Azzi J, Hamadani M, Logan B, Ahmed S, Bharadwaj S, Baird JH, Jacobson C, Locke FL, Ulrickson M, Reagan PM, Hemmer MT, Hu ZH, Luo ZC, Wang HL, Jung AS, Nahas M, Best T, Beygi S, Pasquini MC. Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis. Transplant Cell Ther. 2026 May.32(5):623.e1-623.e15. Pubmedid: 41525947.
• Drekolias D, Tuz Zahra F, Fileni C, Sallman DA, Mo Q, Chan O, Zhang L, Vincelette ND, Yu X, Sammut R, Moon J, Park J, Umasangtongkul SA, Lledo FM, Razabdouski TN, Cheng CH, Qin D, Mai K, Ball S, Shallis RM, Xie Z, Kuykendall AT, Padron E, Sweet K, Walker AR, Komrokji RS, Lancet JE, Niyongere S, Cluzeau T, Yun S. Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents. Blood Cancer Discov. 2026 May.7(3):403-413. Pubmedid: 41671569. Pmcid: PMC12967238.
• Medina E, Mason C, Tran TH, Juliá EP, Ming Q, Taibi LM, Hwu P, Maute RL, Burg JS, Luca VC. Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10. Structure. 2026 May.34(5):768-777.e5. Pubmedid: 41747717.
• Nusbaum DJ, Li R, Peyton CC, Spiess PE. Less Is More? How Much Bacillus Calmette-Guérin (BCG) Is Enough for BCG-naïve High-risk Non-muscle invasive Bladder Cancer?. Eur Urol. 2026 May.89(5):454-456. Pubmedid: 41741295.
• Li T, Brönimann S, Cheaib J, Matin SF, Spiess PE, Li R, Clark R, Raman J, Hensley P, Coleman J, Margulis V, Potretzke AM, Hoffman-Censits J, Singla N. Is More Better? Evaluating Neoadjuvant Chemotherapy Cycles Before Surgery for High-Risk Upper Tract Urothelial Carcinoma. Urol Oncol. 2026 May.44(5):111040. Pubmedid: 41764971.
• Sondak VK, Clune JE. Gene Expression Profile-Based Tests in Melanoma: What Factors Really Matter and How Do We Evaluate Them?. Ann Surg Oncol. 2026 May.33(5):3787-3789. Pubmedid: 41795051.
• Medina CB, Sobierajska E, Gong M, McManus DT, Thapa M, Lee J, Im SJ, Toombs JE, Mitchell JM, Wang Y, Carlisle JW, Freeman GJ, Master VA, Ramalingam SS, Kissick HT, Li S, Brekken RA, Ahmed R. Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion. Nature. 2026 May.653(8115):879-887. Pubmedid: 41882354.
• Zhang Z, Ho YJ, Fang X, Kim M, Li M, Luan W, Hinterleitner C, Haubner S, Kogel F, Pratt EC, Ozcelik E, Reyes J, Jiang Q, Yang VW, Chen YJ, Wang T, Liu H, Hu H, Zhuang X, Park J, Paffenholz SV, Chen K, Chang Q, Kulick A, Zhang J, Chan E, Rosiek E, Fan N, Williams RA, Wang AC, Freeman S, Tian S, Gunset G, Garcia Angus A, Lecomte N, Yildirim SY, Ali E, Wu M, Miranda IC, Antonescu CR, Basturk O, Tarcan Z, Rekhtman N, Wilson C, Basar M, Sauter JL, Al-Ahmadie HA, Singer S, Iacobuzio-Donahue C, Rudin C, de Stanchina E, Ganesh K, Romesser PB, Weigelt B, Huh DD, Leibold J, Feucht J, Vázquez-García I, Bott MJ, Zamarin D, Shah SP, Lewis JS, Amor C, Pe'er D, Mansilla-Soto J, Filliol A, Sadelain M, Lowe SW. A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell. 2026 May.189(10):2898-2917.e42. Pubmedid: 41916312.
• Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, Kött J, Zell T, Amaral T, Ascierto PA, Corrie P, Dummer R, Eggermont A, Guo J, Hassel JC, Jalving M, Johnson DB, Kandolf L, Kirkwood JM, Lebbé C, Lee R, Long GV, Lorigan P, Malvehy J, Mangana J, Mohr P, Patel SP, Rizos H, Robert C, Schadendorf D, Sondak VK, Svane IM, Wainstein A, Zager JS, Pantel K, Hauschild A, Gebhardt C. Translating ctDNA into cutaneous melanoma care: An international expert survey. Eur J Cancer. 2026 May.239:116676. Pubmedid: 41932032.
• Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F. Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age. Leukemia. 2026 May.40(5):1009-1017. Pubmedid: 41986623. Pmcid: PMC13148988.
• Patra P, Jacome M, Ahmed KA, Yang JT, Smalley I, Forsyth PA, Piña Y. A New Era in Leptomeningeal Disease (LMD): Recent Advancements in Immunocellular and Radiation Therapies in Melanoma LMD, What Has Been Done and Future Directions. Pigment Cell Melanoma Res. 2026 May.39(3):e70082. Pubmedid: 42003166.
• Bryant JM, Sandoval M, Putney R, Trivedi P, Katende EN, Fink A, Naqvi SM, Kim Y, Yin V, Zhang J, Park JY, Serna A, Lam N, Pow-Sang J, Poch M, Li R, Manley BJ, Naghavi A, Torres-Roca J, Grass GD, Kim S, Latifi K, Hunt D, Johnstone P, Dhillon J, Rodriguez PC, Jain R, Fernandez DC, Yamoah K. Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. J Immunother Cancer. 2026 May.14(5). Pubmedid: 42082271. Pmcid: PMC13141221.
• Giatsoglou M, Chatzistavrou D, Sopczynski JM, Feng G, Li R. Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer. JAMA Netw Open. 2026 Apr.9(4):e267470. Pubmedid: 41989781. Pmcid: PMC13087816.
• Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp MS, Houot R, Beitinjaneh A, Zheng D, Chang M, Zhang W, Shen RR, Khalid RD, Kloos I, Wang ML. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. J Hematol Oncol. 2026 Apr.19(1). Pubmedid: 42036693. Pmcid: PMC13242663.
• Zhang Y, Sokol L. Revisiting the Origins of Cutaneous T-Cell Lymphoma: A Progenitor-Based Model. Cancers (Basel). 2026 Apr.18(9). Pubmedid: 42122188. Pmcid: PMC13162749.
• Lee WJ, Asghar MS, Park R, Won SH, Shahzad M, Shimshak T. Externally Validated Machine Learning Models for 30-/90-/180-Day Unplanned Readmission After Head and Neck Cancer Hospitalizations in the United States. JCO Clin Cancer Inform. 2026 Apr.10(2):e2500335. Pubmedid: 42284547. Pmcid: PMC13268123.
• Pichler R, van Creij NCH, Mertens LS, Del Giudice F, Koll F, Soria F, Subiela JD, Plage H, Tymoszuk P, Mayr R, Klinglmair G, Seeber A, Pichler M, Günther M, Ormanns S, Compérat E, Li R, Moschini M, Pradére B. FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma. Eur Urol Oncol. 2026 Apr.9(2):220-226. Pubmedid: 40716983.
• Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2026 Apr.49(4):176-187. Pubmedid: 40905435. Pmcid: PMC13011960.
• Jazayeri B, Wang X, Li R. Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. Eur Urol. 2026 Apr.89(4):e95-e96. Pubmedid: 41107180.
• Akahoshi Y, Bejanyan N, Nakasone H, Kusuda M, Tada Y, Sakaida E, Atsuta Y, Kanda Y, Fukuda T. Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis. Transplant Cell Ther. 2026 Apr.32(4):501.e1-501.e10. Pubmedid: 41352454. Pmcid: PMC12698115.
• Philbrook P, Dean MJ, Sanchez-Pino MD, Zheng LQ, Zabaleta J, Vázquez-Martínez JA, Chang D, Mandula JK, Shaw TI, Wyczechowska D, Garai J, Thylur Puttalingaiah R, Mansouri A, Huang W, Das S, Chang S, Conejo-Garcia JR, Rodriguez PC, Ochoa AC. Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer Immunol Res. 2026 Apr.14(4):640-657. Pubmedid: 41557755. Pmcid: PMC12990994.
• Ordobazari A, Nikfar R, Zhao X, Davaro E, Niyazi S, Rogers JE, Dhillon J, Cao B, Li R, Spiess PE, Pow-Sang JM, Adeniran A, Jorda M, Vosoughi A. Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria. Diagn Cytopathol. 2026 Apr.54(4):299-306. Pubmedid: 41567090.
• Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu KS, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Odstrcil Bobillo S, Hilal T, Park JH, Valtis YK, Faramand RG, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine JP, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran M, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock WA, Schwartz MS, Byrd K, Yalniz FF, Bachanova V, Tracy SI, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai C, Muffly LS. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr.147(17):2011-2017. Pubmedid: 41643192.
• Pinilla-Ibarz J, Xue M, Wu E, Esselman K, Furnback W, Challagulla S, Yang K. Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma. Expert Rev Hematol. 2026 Apr.19(4):457-464. Pubmedid: 41662512.
• Gathirua-Mwangi W, Kim S, Martin H, Lokhandwala T, Zheng S, Farrelly E, Brechtelsbauer E, Rybowski S, Ahmed KA. Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2- Metastatic Breast Cancer in the Real-World Setting. Adv Radiat Oncol. 2026 Apr.11(4):101992. Pubmedid: 41732736. Pmcid: PMC12925158.
• Baumrucker C, Relation T, Czerniecki BJ. Dendritic Cell-Based Immunotherapy for Solid Tumors. Surg Oncol Clin N Am. 2026 Apr.35(2):271-283. Pubmedid: 41903989.
• Contieri R, Gontero P, Hurle R, Afferi L, Albisinni S, Babjuk M, Birtle A, Black P, Brausi M, Bruins M, Čapoun O, Carrion A, Catto J, Choudhury A, Cimadamore A, Comperat E, Daneshmand S, D'andrea D, Del Giudice F, Escrig JLD, Hensley P, Krajewski W, Laukhtina E, Li R, Liedberg F, Lotan Y, Marcq G, Mariappan P, Mari A, Martini A, Lecomte AM, Meijer R, Mir MC, Mori K, Moschini M, Mostafid H, O'Donnell M, Palou J, Panebianco V, Perdonà S, Porten S, Psutka S, Rink M, Roupret M, Seisen T, Soloway M, Soukup V, Steinberg G, Stenzl A, Teoh JY, Tully K, van der Heijden T, van Rhijn BWG, Witjes A, Xylinas E, Kamat AM, Pradere B, Mertens LS. Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus. Nat Rev Urol. 2026 Apr. Pubmedid: 41922791.
• Huynh THN, Clampitt BA, Chose CM, Nester MD, Joyce DM, Binitie OT, Freeman CL, Lazarides AL. Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma. J Am Acad Orthop Surg. 2026 Mar.34(6):e926-e933. Pubmedid: 40953403.
• Perez DH, Antfolk D, Chang S, Bustos XE, Medina E, Ramadan AA, Gonzalez-Perez D, Abate-Daga D, Rodriguez PC, Luca VC. Engineering synthetic agonists for targeted activation of Notch signaling. Nat Chem Biol. 2026 Mar.22(3):392-401. Pubmedid: 40993428. Pmcid: PMC12953149.
• Potez M, Roman Souza G, Spiess PE, Pilon-Thomas S, Chahoud J. The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. Nat Rev Urol. 2026 Mar.23(3):196-212. Pubmedid: 41006825.
• Harris N, Aiello P, Detz D, Whiting J, Sun W, Hoover S, Khakpour N, Kiluk J, Kruper L, Laronga C, Mallory M, Mooney B, Czerniecki B, Lee MC. Non-Wire Bracketed Localization Techniques and Decreased Margin Positive Rates in Breast Cancer. Clin Breast Cancer. 2026 Mar.26(3):128-132. Pubmedid: 41188088.
• Kho SJ, Diamond SS, Lafeuille P, Schatz JH, Maura F, Aptekar J, Locke FL. Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials. Blood Adv. 2026 Mar.10(5):1497-1507. Pubmedid: 41201393. Pmcid: PMC12952768.
• Dehn JG, Logan B, Lee SJ, Shaw BE, Devine S, Ciurea SO, Horowitz M, He N, Pusic I, Srour SA, Arai S, Juckett M, Uberti J, Hill L, Vasu S, Hogan WJ, Hayes-Lattin B, Westervelt P, Bashey A, Farhadfar N, Grunwald MR, Leifer E, Symons H, Saad A, Vogel J, Erickson C, Buck K, Pidala J. Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial. Transplant Cell Ther. 2026 Mar.32(3):346-357. Pubmedid: 41213499. Pmcid: PMC12779121.
• Zhao D, Khatri VM, Nakashima JY, Chadha J, Chatwal M, Zhang J, Ionescu F, Linscott JA, Li R, Poch M, Sexton W, Yu A, Spiess PE, Zemp L, Gilbert SM, Manley B, Yin V, Jain R, Torres-Roca J, Johnstone P, Yamoah K, Grass GD. Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy. J Urol. 2026 Mar.215(3):305-315. Pubmedid: 41231842.
• Jacobson CA, Westin JR, Miklos DB, Herrera AF, Ritz J, Rodig S, Arihara Y, Cao S, Sun J, Mao D, Adhikary S, Neumann F, Grechko N, Locke FL. Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial. Clin Cancer Res. 2026 Mar.32(5):894-904. Pubmedid: 41231109. Pmcid: PMC13056289.
• Harris N, Aiello P, Detz D, Hanssen D, Farrell C, Balsay-Patel C, Whiting J, Hoover S, Khakpour N, Kiluk J, Kruper L, Laronga C, Mallory M, Lee MC, Czerniecki B. Postoperative Impact of Closed Incision Negative Pressure Therapy Following Oncoplastic Breast Surgery. Ann Surg Oncol. 2026 Mar.33(3):2013-2018. Pubmedid: 41241710.
• Dugan MM, Balsay-Patel C, Chin N, Israeli J, Ward KR, Nichols M, Greenbaum S, Fan W, Cruse CW, Harrington M, Neves RI, Gonzalez RJ, Perez MC, Sarnaik AA, Sondak VK, Messina JL, Tarhini AA, Khushalani N, Brohl AS, Markowitz J, Eroglu Z, Karapetyan L, Tsai KY, Zager JS. ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2026 Mar.33(3):2596-2597. Pubmedid: 41361154.
• Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar.147(11):1168-1177. Pubmedid: 41385341. Pmcid: PMC13123417.
• Bangs R, Li R. Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast). Oncol Ther. 2026 Mar.14(1):73-80. Pubmedid: 41398139. Pmcid: PMC12992752.
• Harris N, Aiello P, Detz D, Hanssen D, Farrell C, Balsay-Patel C, Whiting J, Hoover S, Khakpour N, Kiluk J, Kruper L, Laronga C, Mallory M, Lee MC, Czerniecki B. ASO Visual Abstract: Post-operative Impact of Closed Incision Negative Pressure Therapy Following Oncoplastic Breast Surgery. Ann Surg Oncol. 2026 Mar.33(3):2031-2032. Pubmedid: 41413279.
• Prabhakaran S, Gatenbee CD, Robertson-Tessi M, Gahramanli Ozturk Z, Boyle TA, Gray JE, Antonia SJ, Gatenby RA, Beg AA, Anderson ARA. Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response. Cancer Res. 2026 Mar.86(5):1269-1285. Pubmedid: 41418101. Pmcid: PMC12871056.
• Karapetyan L, Kuriakose J, DiMaggio E, Ward K, Chau J, Otteni C, Kalos D, Ali J, Hall MS, Beatty M, Klinkova OV, Alomar ME, Gaskill EE, Gonzalez RM, Bailey H, Yu M, Tran N, Rodriguez-Alfonso L, Vieira E, Adams K, Jain M, Locke FL, Baldonado J, Perez MC, Mullinax J, Zager JS, Gonzalez R, Sondak VK, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients. Transplant Cell Ther. 2026 Mar.32(3):290.e1-290.e14. Pubmedid: 41421538.
• Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, Park D, Babu S, Ju Y, Liu L, Henry S, Tirucherai GS, DeWall S, Qatanani M, Marantz JL, Gan L. Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026 Mar.32(3):992-1001. Pubmedid: 41530380. Pmcid: PMC13004668.
• Cao B, Yu X, Gonzalez G, Murthy AR, Li T, Shen Y, Yao S, Wang X. CGPA: A Multicontext Cancer Gene Prognosis Atlas. Mol Cancer Res. 2026 Mar.24(3):188-197. Pubmedid: 41528384. Pmcid: PMC12908732.
• Joshi U, Ong F, Melzer D, Ma JC, Saltos A, Chiappori A, Creelan B, Pellini B, Lu C, Haura E, Shafique M, Tanvetyanon T, Kareem SS, Budhathoki P, Solarte DCB, Naqvi SMH, Puglianini OC, Gaballa S, Gray JE, Puri S. Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use. Clin Lung Cancer. 2026 Mar.27(2):48-58. Pubmedid: 41544604.
• Gaál Z, Meehan C, Yilmaz M, Ujhazi B, Suhet P, Miller R, Dasso J, Nomula K, Franson B, Toth M, Potts E, Gokbak MN, Gordon S, Ellison M, Cruz R, Asante-Korang A, Cassani FA, Betensky M, Butte M, Cooper MA, Cockrell E, Galligan A, Glaum M, Grimbacher B, Fliegauf M, Meyer A, Milojevic D, Minor M, Mendez EM, Metts J, Nieves D, Ong MS, Oshrine BR, Patel P, Prpich J, Purser J, Ramirez A, Rosenberg D, Schlefman A, Shaker A, Shah S, Shah B, Santiago L, Obzut D, Sriaroon P, Thatayatikom A, Weis E, Mayer J, Farmer JR, Csomos K, Eslin D, Ayala I, Westermann-Clark E, Walter JE. Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia. Pediatr Blood Cancer. 2026 Mar.73(3):e70074. Pubmedid: 41560547.
• Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, Kipnis J, Colonna M, Brioschi S. Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. Nat Neurosci. 2026 Mar.29(3):717-731. Pubmedid: 41566006.
• Oswald LB, Li X, Ferraris CE, DeAvila G, Scheiber-Camoretti D, Gudenkauf LM, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker N, Carson TL, Vinci CE, Baz RC, Shain KH, Blue BJ, Grajales-Cruz AF, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini OA, Nishihori T, Liu HD, Locke FL, Jim HS, Hansen DK, Peres LC. Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity. Blood Adv. 2026 Mar.10(6):1959-1963. Pubmedid: 41564433. Pmcid: PMC12995473.
• Babu V, Shin DB, Onstad L, Pidala JA, Chen G, Lee CJ, Kitko CL, Carpenter PA, Cutler C, El Jurdi N, Loren AW, Gelfand JM, Lee SJ, Baumrin E. Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease. JAMA Dermatol. 2026 Mar.162(3):245-254. Pubmedid: 41563741. Pmcid: PMC12824848.
• Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, Kipnis J, Colonna M, Brioschi S. Publisher Correction: Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. Nat Neurosci. 2026 Mar.29(3):761. Pubmedid: 41644654.
• Mehta RS, McCurdy SR, Milano F, Nawas M, Aljawai Y, Rimando JC, Al-Juhaishi T, Im A, Kanakry JA, Lazaryan A, Kanakry CG. Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection. Leukemia. 2026 Mar.40(3):689-693. Pubmedid: 41663621. Pmcid: PMC12960218.
• Faramand RG, Xie Z, Jain MD. Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. J Clin Oncol. 2026 Mar.44(8):698-708. Pubmedid: 41671523.
• Nowak JA, Cho E, Davis MA, Zheng S, Bell L, Sha F, Magdalenski JS, Lui A, Napoli M, Falahat R, Mulé JJ, Flores ER, Farha OK, Teplensky MH. Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles. Nano Lett. 2026 Mar.26(8):2861-2868. Pubmedid: 41712689.
• Garg SK, Snyder C, Ramamoorthi G, Kodumudi KN, Evans EE, Lok V, Bussler H, Nguyen JV, Yao J, Basu A, Gautam N, Vazquez Martinez JA, Chang DC, Aldrich AL, Wiener D, Rodriguez PC, Zauderer M, Koski GK, Czerniecki BJ. Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. Cell Rep. 2026 Mar.45(3):117050. Pubmedid: 41785084.
• Khatri VM, Aboujaoude M, Karapetyan L, Tarhini AA, Brohl AS, Eroglu Z, Markowitz J, Rayn K, Khushalani NI, Wuthrick EJ, Yu HM, Oliver DE, Ahmed KA. Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression. J Neurooncol. 2026 Mar.177(1). Pubmedid: 41801545.
• van Creij NCH, Tymoszuk P, Handle F, Seeber A, Sellemond T, Martowicz A, Comperat E, Wafa H, Ormanns S, Günther M, Parson W, Noeparast M, Santer FR, Subiela JD, Grivas P, Li R, Culig Z, Pichler R. Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. Clin Transl Med. 2026 Mar.16(3):e70638. Pubmedid: 41804750. Pmcid: PMC12973134.
• Mercinelli C, Pavlick D, Agarwal N, Spiess PE, Li R, Kamat AM, Grivas P, Gupta S, Maiorano BA, Tateo V, Cigliola A, Piacentini M, Jacob JM, Bratslavsky G, Basnet A, Ross JS, Necchi A. Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy. Oncologist. 2026 Mar.31(4). Pubmedid: 41871940.
• Pidala JA, Varadhan R, Jones RJ. Donor type outcomes in setting of PTCy: more apparent than real?. Blood Adv. 2026 Mar.10(6):2122-2123. Pubmedid: 41874520. Pmcid: PMC13045608.
• Harman RC, Lozano I, Ramos K, Quilez-Alburquerque J, Gagnon J, Cheung S, Otero N, Johnson-Shoucair A, Kercher EM, Harris JE, Rizvi I, Pilon-Thomas S, Enderling H, Hasan T, Spring BQ. Cancer-selective photoimmunotherapy spares T cells and NK cells and promotes antitumor immunity in an allogeneic human 3D culture model. Photochem Photobiol. 2026 Mar. Pubmedid: 41889218.
• Khaksar MA, Eljilany I, Yassine I, Yu X, Teer JK, Conejo-Garcia JR, Lyons M, LaFramboise W, Tarhini AA. Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with Ipilimumab. J Clin Med. 2026 Mar.15(6). Pubmedid: 41899279. Pmcid: PMC13026618.
• Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, Wright C, Blue BJ, Baz RC, Shain KH, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Garcia-Pleitez H, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson LD, Julian K, Dima D, Banerjee R, Liang EC, Cassano Cassano R, Herr MM, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke FL, Hansen DK, Sborov D, Biran N, Grajales-Cruz A. Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2026 Mar.16(1). Pubmedid: 41896552. Pmcid: PMC13039266.
• Zhang T, Han K, Du S, Xue W, Wang Y, Wang Z, Zhang Y. EPR26-171: Uncovering the Roots of Survival Disparities in Mycosis Fungoides: A Population-Based Analysis Using the Surveillance, Epidemiology, and End Results (SEER) and National Inpatient Sample (NIS) Databases. J Natl Compr Canc Ne. 2026 Mar.24(3.5). Pubmedid: 41911770.
• Oluwatola O, Bazargan S, Irrera P, Chang D, Thomas A, Blauvelt J, Beatty M, Hall M, Whelan CJ, Estrella V, Rejniak KA, Poch M, Fitzsimmons N, Beal R, Ibrahim-Hashim A, Pilon-Thomas S. Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer. Front Immunol. 2026 Mar.17:1706250. Pubmedid: 41909665. Pmcid: PMC13021593.
• Olumoyin KD, Aydin AM, Bazargan S, Bunch B, Chamseddine I, Karolak A, Beatty M, Pilon-Thomas S, Poch MA, Rejniak KA. PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers. bioRxiv. 2026 Mar. Pubmedid: 41959383. Pmcid: PMC13060882.
• Anderson HG, Bazargan S, Nusbaum DJ, Poch MA, Pilon-Thomas S, Rejniak KA. A virtual cohort framework with applications to adoptive cell therapy in bladder cancer. bioRxiv. 2026 Mar. Pubmedid: 41959223. Pmcid: PMC13060980.
• Calescibetta A, Dalton R, Fortenbery N, Ward G, Christiansen S, Chen X, Cheng P, Razabdouski T, Glode AJ, Tu N, Le Trinh T, Liu J, Wright KL, Wei S, Eksioglu EA. Correction: Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PLoS One. 2026 Mar.21(4):e0348020. Pubmedid: 42018535. Pmcid: PMC13102199.
• Martinez-Planes E, Ramello MC, Fontela MG, Shokri MR, Darville L, Koomen J, Kim Y, Abate-Daga D. C-terminus CD28 phosphorylation (Y218) modulates IL-2 secretion and antitumor effect of CAR-T cells. bioRxiv. 2026 Feb. Pubmedid: 41659581. Pmcid: PMC12874040.
• Perez XB, Tordesillas L, Martinez-Planes E, Fontela MG, Rossetti RM, Izumi V, Fang B, Koomen J, Welsh E, Hwu P, Abate-Daga D. CAR Signaling Informs Mechanisms to EnhanceMetabolism and Function in γδ T Cells. Res Sq. 2026 Feb. Pubmedid: 41674831. Pmcid: PMC12889835.
• Ramadoss T, Palacios C, Nichols M, Eroglu Z, Markowitz J, Karapetyan L, Tarhini AA, Wuthrick EJ, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. Cancer Immunol Immun. 2026 Feb.75(3):73. Pubmedid: 41677907. Pmcid: PMC12900986.
• Soyano Muller AE, Goodridge DN, Mo Q, Whiting J, Khakpour N, Lee MC, Laronga C, Armaghani AJ, Han H, Soliman H, Costa R, Loftus L, Hoover SJ, Kiluk JV, Jameel Z, Czerniecki BJ, Khong HT. Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2026 Feb.216(1):11. Pubmedid: 41697438.
• Buchbinder EI, Song Z, Cohen JV, Lee SJ, Smith KK, Manos M, Tarhini A, Dougan M. Impact of immune checkpoint inhibition on ovarian reserve. Oncologist. 2026 Feb.31(3). Pubmedid: 41701163. Pmcid: PMC12959320.
• Pidala J, Onstad L, Carpenter P, Hamilton BK, Kitko CL, Juckett M, Cutler C, Lee SJ. Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium. Transplant Cell Ther. 2026 Feb.32(2):205.e1-205.e12. Pubmedid: 41706088. Pmcid: PMC12917312.
• Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial. Res Sq. 2026 Feb. Pubmedid: 41727611. Pmcid: PMC12919184.
• Sallman DA, McLemore AF, Komrokji R, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala J, Yoder SJ, Perez L, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A. Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes. Blood Adv. 2026 Feb.10(4):1053-1057. Pubmedid: 41733970.
• Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang J, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami G, Chen-Kiang S, Elemento O, Maddocks K, Leonard JP, Martin P. MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. Blood Adv. 2026 Feb.10(4):1381-1394. Pubmedid: 41733969.
• Eljilany I, Jafari E, Alhumaid A, Eroglu Z, Brohl AS, Karapetyan L, Markowitz J, Khushalani NI, Hwu P, Tarhini AA. Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2026 Feb.18(4). Pubmedid: 41749963. Pmcid: PMC12938985.
• Fachi JL, de Oliveira S, Trsan T, Molgora M, Fernandes Rodrigues P, Gilfillan S, Ulezko Antonova A, Chang HW, Penati S, Cao S, Cella M, Colonna M. Divergent ILC3 responses to PDGF-D control mucosal immunity. Sci Immunol. 2026 Feb.11(116):eaea6848. Pubmedid: 41758927.
• Ulschmid C, Li X, Wang T, Logan BR, Pidala JA, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Saber W. Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation. Blood Adv. 2026 Feb.10(4):1348-1360. Pubmedid: 41498421. Pmcid: PMC12927055.
• Fabbroni C, Johnston EW, Sanfilippo R, Strauss DC, Bonvalot S, Spalek M, Van Houdt WJ, Ford SJ, Lee KW, Salawu A, Swallow CJ, Bae S, Gyorki DE, Raut CP, Mullinax JE, Albertsmeier M, Cananzi F, Konieczkowski D, Grignol VP, Pennacchioli E, Solli P, Napolitano A, Blasi ED, Wilkinson M, Stacchiotti S, Tzanis D, Rutkowski P, Bouhadiba T, Schrage YM, Sherriff J, Wang J, Callegaro D, Farma JM, Fiore M, Gervais MK, Gladdy RA, Nessim C, Roland CL, Cranmer LD, Lee TY, Patel S, von Mehren M, Wagner AJ, Sicklick JK, Gronchi A, Tseng WW. Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG). Cancer Treat Rev. 2026 Feb.143:103086. Pubmedid: 41506129.
• Desai D, Sager RA, Basin M, Jacob JM, Morris GJ, Spiess PE, Li R, Cheng L, Necchi A, Kamat AM, Grivas P, Pavlick D, Goldberg H, Mollapour M, Lin D, Ross JS, Bratslavsky G, Basnet A, Daneshvar MA. Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors. Oncologist. 2026 Feb.31(3). Pubmedid: 41557860. Pmcid: PMC12923112.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Feb.7(2):272-282. Pubmedid: 41611998. Pmcid: PMC12948668.
• Hamaidi I, Cheng P, Jun SY, Manna A, Wang MH, Nguyen A, Can I, Zhang MG, Taylor OO, Bailon LUL, Fang B, Perez B, Creelan BC, Marusyk A, Shin D, Hwang TH, Berglund AE, Shapiro VS, Ji HM, Conejo-Garcia JR, Kim S. SIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling. Nat Immunol. 2026 Feb.27(2):213-224. Pubmedid: 41611868. Pmcid: PMC12864039.
• Thida AM, Shah A, Steffens KF, Watters S, Duan M, Devine S, Vadaparampil ST, Pidala J. Trends in US Hematology/Oncology Physician Perceptions and Referral Practices for Hematopoietic Cell Transplant: A National Survey Conducted by NMDP. Cancer Med. 2026 Feb.15(2):e71551. Pubmedid: 41607247. Pmcid: PMC12853074.
• Chavez JC, Napier E, Bondanza A, Lewandowski A, Mataraza J, Quinn D, Kwon P, Locke FL, Engels B, Awasthi R, Georgala P, Leyk M, Hynds D, Moschetta M, Schuster SJ. Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. Blood Neoplasia. 2026 Feb.3(1):100176. Pubmedid: 41536778. Pmcid: PMC12796982.
• Perez MC, Zager JS. Management of In-Transit Metastatic Melanoma. Hematol Oncol Clin North Am. 2026 Feb.40(1):89-99. Pubmedid: 41224445.
• Bryant JM, Shotbolt M, Stimphil E, Andre V, Zhang E, Estrella V, Husain K, Weygand J, Marchion D, Lopez AS, Abrahams D, Chen S, Abdel-Mottaleb M, Conlan S, Oraiqat I, Khatri V, Guevara JA, Pilon-Thomas S, Redler G, Latifi K, Raghunand N, Yamoah K, Hoffe S, Costello J, Frakes JM, Liang P, Gatenby RA, Malafa M, Khizroev S. Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models. Adv Sci (Weinh). 2026 Feb.13(9):e17228. Pubmedid: 41178530. Pmcid: PMC12904064.
• Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A. Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes. Blood Adv. 2026 Feb.10(4):1053-1057. Pubmedid: 41289162. Pmcid: PMC12915186.
• Ruan J, Bond DA, Shah BD, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang JZ, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami GG, Chen-Kiang S, Elemento O, Maddocks KJ, Leonard JP, Martin P. MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. Blood Adv. 2026 Feb.10(4):1381-1394. Pubmedid: 41289154. Pmcid: PMC12927050.
• Hall K, Lazaryan A, Der Laan MV, Lee CJ, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota LM, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States. Blood Adv. 2026 Feb.10(3):682-693. Pubmedid: 40875591. Pmcid: PMC12870858.
• Ardila V, Onstad L, Carpenter P, Pidala J, Kitko C, Jurdi NE, Lee SJ, Hamilton BK. Obesity Associations with Chronic Graft-Versus-Host Disease. Transplant Cell Ther. 2026 Feb.32(2):177.e1-177.e10. Pubmedid: 40998267.
• Myers AA, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore N, Steinberg GD, Witjes JA, Schmidt B, Porten S, Hahn NM, Bree KK, Toumazis I, Zhao H, Kamat AM. Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder. Eur Urol. 2026 Feb.89(2):151-162. Pubmedid: 41046180.
• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
• Alduaij W, Sehn LH, Champagne JN, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Savage KJ, Villa D, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Scott DW. Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology. Blood Adv. 2026 Jan.10(2):320-333. Pubmedid: 41071951. Pmcid: PMC12828750.
• Gaskill E, Albanyan O, Naqvi SMH, Mo Q, Belfon A, Nishihori T, Faramand R, Lazaryan A, Hansen DK, Khimani F, Mishra A, Nieder M, Perez L, Liu H, Pidala J, Anasetti C, Bejanyan N, Elmariah H. Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia. Transplant Cell Ther. 2026 Jan.32(1):78.e1-78.e11. Pubmedid: 41115629.
• Gravenmier C, Marzban S, Tang YH, Gillis N, Shah BD, Moscinski LC, Zhang L, West J. Cell State Transitions Drive the Evolution of Disease Progression in B-Lymphoblastic Leukemia. Cancer Res Commun. 2026 Jan.6(1):47-59. Pubmedid: 41295979. Pmcid: PMC12775648.
• Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquières H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janíková A, Mocikova H, Fürst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. J Clin Oncol. 2026 Jan.44(2):117-128. Pubmedid: 41329901. Pmcid: PMC12674000.
• Johnson NA, Zinzani PL, Domingo-Domenech E, Brody J, Kline J, Shah BD, Mehta AN, Ghesquieres H, Savage KJ, Barr PM, Santoro A, Ferrari S, Cunningham D, Collins GP, Fanale M, Krajewski J, Akyol A, Crowe R, Wen R, Kuruvilla J. Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma. Future Oncol. 2026 Jan.22(1):93-99. Pubmedid: 41367262. Pmcid: PMC12773585.
• McKay RR, Pal S, Xie W, Aggen D, Albiges L, Apolo A, Atkins MB, Bangs R, Beckermann KE, Bellmunt J, Berg SA, Bilen MA, Braun D, Carlo MI, Efstathiou J, Galsky M, Grivas P, Gupta S, Haas N, Hakimi AA, Hammers H, Heng DYC, Hirsch M, Iyer G, Jonasch E, Koshkin VS, Kryvenko O, Lewis B, Li R, Matin S, Maughan B, McDermott DF, McGregor B, Meeks J, Milowsky M, Motzer R, Necchi A, Petrylak D, Porten S, Powles T, Rini B, Shuch B, Siefker-Radtke A, Sonpavde G, Sridhar SS, Suarez C, Tang C, Tripathi A, Van Der Heijden MS, Voss M, Xu W, Zhang T, Rosenberg J, Choueiri TK. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA-Cancer J Clin. 2026 Jan.76(1):e70052. Pubmedid: 41389316. Pmcid: PMC12701758.
• Harrs CF, Pusala S, Cheng L, Jazayeri B, Li R. Recent advances in liquid biopsy for genitourinary cancers: A narrative review. Histopathology. 2026 Jan.88(1):338-352. Pubmedid: 41384686.
• Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdés A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026 Jan.89(1):18-28. Pubmedid: 40268594.
• Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica. 2026 Jan.111(1):184-195. Pubmedid: 40637727. Pmcid: PMC12775792.
• Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2026 Jan.12(1):38-40. Pubmedid: 40716995.
• Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen AF, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Ramakrishnan Geethakumari P, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse CS, Turtle CJ, Valluripalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror ML. New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026 Jan.10(1):217-227. Pubmedid: 40811818. Pmcid: PMC12811452.
• Lehner K, Li R, Hensley PJ, Clark RK, Pallauf M, Katims A, Bingham N, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Smoking is Associated With Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial Cancer. Urology. 2026 Jan.207:186-192. Pubmedid: 40848880.
• Dineen S, Mullinax J. ASO Author Reflections: Emphasizing Surgical Palliative Care in CGSO Fellowship Programs. Ann Surg Oncol. 2026 Jan.33(1):39-40. Pubmedid: 40924245.
• Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R. Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2026 Jan.137(1):181-188. Pubmedid: 40932312.
• Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2026 Jan.147(5):497-512. Pubmedid: 40983035.
• Titus RS, Mundra V, Velasquez EL, Xu J, Riveros C, Ranganathan S, Porika A, Reddy R, Kaushik D, Kukreja J, Li R, Wallis CJD, Satkunasivam R. The association between prior pelvic radiotherapy for cancer and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: An analysis of national surgical quality improvement program targeted cystectomy database. Urol Oncol. 2026 Jan.44(1):62.e9-62.e16. Pubmedid: 41006132.
• Louloudis IE, Chen YB, Spyrou N, Alousi A, Katsivelos N, Ayuk F, Weber D, Hogan WJ, Etra AM, Qayed M, Aguayo-Hiraldo P, Akahoshi Y, Malki MMA, Bolaños-Meade J, Chanswangphuwana C, Diniz M, Eder M, Hexner E, Kitko CL, Kraus S, Merli P, Olson T, MacMillan ML, Pidala J, Reshef R, Schechter T, Wölfl M, Baez J, Eng G, Gleich S, Young R, Nakamura R, Ferrara JLM, Levine JE. Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity. Transplant Cell Ther. 2026 Jan.32(1):63.e1-63.e11. Pubmedid: 41015085. Pmcid: PMC12636002.
• Valtis YK, Lin C, Nemirovsky D, Devlin SM, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi A, Muhsen IN, Sasine JP, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar NE, Tsai SB, Hilal T, Shah BD, Faramand RG, Solh MM, Tan V, Bezerra ED, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy PJ, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran M, Schwartz MS, Tracy SI, Moore J, Odstrcil Bobillo S, Frey NV, Connor MP, Ladha A, Dholaria B, Sutherland KC, Roloff GW, Muffly LS, Park JH. CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood Adv. 2026 Jan.10(1):276-288. Pubmedid: 41052404. Pmcid: PMC12848364.
• Bosquet JG, Osazuwa-Peters O, Wagner VM, Polio A, Hoyd R, Tarhini AA, Cosgrove CM, Huang MS, Corr BR, Leiser AL, Salhia B, Darcy K, Dood RL, Dockery LE, Cavnar MJ, Landrum L, Chambers L, Tan AC, Jin N, Rounbehler RJ, Churchman ML, Spakowicz D. Intrinsic tumor factors and extrinsic environmental and social exposures contribute to endometrial cancer recurrence patterns. Res Sq. 2026 Jan. Pubmedid: 41646408. Pmcid: PMC12869553.
• Soyano A, Lee MC, Han HS, Aldrich A, Soliman H, Olson-Mcpeek SK, Balsay-Patel CN, Aiello P, Farrell CM, Weinfurtner R, Burgos E, Czerniecki BJ, Ramamoorthi G. Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer. J Immunother Cancer. 2026 Jan.14(1). Pubmedid: 41494747. Pmcid: PMC12778222.
• Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Chatterjee D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodrigues Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real-world survival estimation. NPJ Precis Oncol. 2026 Jan.10(1):54. Pubmedid: 41526666. Pmcid: PMC12877126.
• Pybus A, Kirchgaessner R, Nguyen J, Moran Segura C, Morais Lyra PC, Rose T, Gray J, Goecks J, Markowitz J. Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning models. NPJ Precis Oncol. 2026 Jan.10(1):56. Pubmedid: 41526648. Pmcid: PMC12877019.
• Alonso-Matilla R, Pedro DI, Pepe A, Serrano-Velez J, Dunne M, Nguyen DT, Sawyer WG, Provenzano PP, Odde DJ. Biophysical modeling identifies an optimal hybrid amoeboid-mesenchymal mechanism for maximal T cell migration speeds. Cell Rep. 2026 Jan.45(1):116824. Pubmedid: 41528848. Pmcid: PMC12994749.
• Brohl AS, Sondak VK, Wuthrick EJ, Kim Y, Eroglu Z, Markowitz J, Tarhini AA, Fan W, Martin J, Sneed L, Perez MC, Sarnaik A, Harrington M, Neves RI, Gonzalez RJ, Cruse CW, Zager JS, Tsai KY, Khushalani NI. Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. J Immunother Cancer. 2026 Jan.14(1). Pubmedid: 41534900. Pmcid: PMC12815050.
• Goala P, Zhang Y, Beatty NJ, Pavy A, McSain SL, Sailer CJ, Tariq MJ, Hamid S, Cortes Gomez E, Wang J, Massillon D, Ilecki M, Boucher JC, Savid-Frontera C, Lee SB, Kotani H, Stone ML, Jain MD, Davila ML. IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy. J Clin Invest. 2026 Jan.136(1). Pubmedid: 41165751. Pmcid: PMC12721892.
• Dugan MM, Balsay-Patel C, Chin N, Israeli J, Ward KR, Nichols M, Greenbaum S, Fan W, Cruse CW, Harrington M, Neves RI, Gonzalez RJ, Perez MC, Sarnaik AA, Sondak VK, Messina JL, Tarhini AA, Khushalani N, Brohl AS, Markowitz J, Eroglu Z, Karapetyan L, Tsai KY, Zager JS. Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2026 Jan.33(1):389-396. Pubmedid: 41168606.
• Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, Bolon YT, Lee SJ, Dehn J, Pidala J, Maiers M, Askar M, Malmberg C, Auletta JJ, Stefanski H, Broglie L, Qayed M, Horwitz M, Wilder JS, Gooptu M, Mehta RS, Fernandez-Viña M, Shaw BE, Shaffer BC. Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Transplant Cell Ther. 2025 Dec.31(12):973-988. Pubmedid: 40619101. Pmcid: PMC12344661.
• Doerfler R, Chen J, Kim C, Smith JD, Harris M, Singh KB, Isett B, Dadey RE, Brown DD, Lee AV, Wang X, Spector ME, Kim S, Sridharan S, Contrera K, Smith K, Reeder C, Lyons M, Luo J, Liu S, Zandberg DP, Skinner HD, Zervantonakis IK, Vujanović L, Ferris RL, Seethala RR, Zevallos JP, Luke JJ, Bao R. Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer. Oral Oncol. 2025 Dec.171:107742. Pubmedid: 41213213.
• Kumar NB, Bahl S, Lemay D, Dhillon J, Poch M, Manley B, Li R, Pow-Sang J, Yu A, Whiting J, Schell MJ. Nutritional intake of ω-3 fatty acid intake and clinical grade of prostate cancer. Cancer Epidemiol. 2025 Dec.99:102959. Pubmedid: 41223508.
• Xu X, Jarajapu V, Chadourne M, Soto-Vargas Z, Ochoa-Rios SL, Jasani N, Wang K, Mecozzi N, Yao J, Yu X, Karreth FA. FRA1 drives melanoma metastasis through an actionable transcriptional network. Oncogene. 2025 Dec.44(50):4895-4909. Pubmedid: 41286309. Pmcid: PMC12669035.
• Khatri VM, Mestres-Villanueva MA, Daniel S, Yarlagadda S, Doniparthi A, Upadhyay R, Mills MN, Oliver DE, Yu HM, Palmer JD, Stover DG, Williams NO, Mahtani RL, Ahluwalia MS, Soyano AE, Soliman HH, Han HS, Kotecha R, Beyer SJ, Ahmed KA. Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report. J Neurooncol. 2025 Dec.175(3):1435-1441. Pubmedid: 41026418.
• Hudson K, Gathirua-Mwangi W, Williams LA, Cui ZL, Richey M, Grimes B, Wang J, Liepa AM, Brechtelsbauer E, Volodarsky R, Moreira K, Soliman H. Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis. Oncol Ther. 2025 Dec.13(4):1105-1118. Pubmedid: 41039165. Pmcid: PMC12647491.
• Atallah E, Broder MS, Chan O, Flynn KE, Gilreath JA, Hine M, Hunter AM, Mattson HTD, Mauro MJ, Pinilla-Ibarz J, Rein LAM, Stemper E, Tantravahi S, Yang J, Shah NP. Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase. Hematology. 2025 Dec.30(1):2556506. Pubmedid: 41054963.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Dec.43(12):2298-2310.e6. Pubmedid: 41072416. Pmcid: PMC12614569.
• Li R, Hensley PJ, Babjuk M, Bukavina L, Psutka SP, Lerner SP, O'Donnell MA, Lotan Y, Bree KK, Redorta JP, McConkey DJ, Lee BH, Mariappan P, Mertens LS, Soloway MS, Svatek RS, Tan WS, Williams SB, Gupta S, Buckley R, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Dec.8(6):1685-1695. Pubmedid: 41076366.
• Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med. 2025 Dec.31(12):4301-4309. Pubmedid: 41109920. Pmcid: PMC12705465.
• Hieken TJ, Egger ME, Angeles CV, Hyngstrom JR, Burke EE, Lowe MC, Beasley GM, Bartlett EK, Bresler SC, Harms KL, Zager JS, Lehman JS, Wasif N, Bagaria SP, McMasters KM, Wada DA, Pandalai P, Delman KA, Lee J, Busam KJ, Messina JL, Sondak VK. Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study. JAMA Surg. 2025 Dec.160(12):1358-1366. Pubmedid: 41123931. Pmcid: PMC12547680.
• Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R, Yang K, Saba NS, Tam CS. Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. Leuk Lymphoma. 2025 Dec.66(12):2238-2248. Pubmedid: 40889741.
• Wen L, Miyagi H, Spiess PE, Yu A, Mendelsohn CL, Tan WS, Psutka SP, Lerner SP, Cheng L, Dyrskjøt L, Meeks JJ, Shariat SF, Gontero P, Pradere B, Steinberg GD, Kamat AM, Li R. Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Nat Rev Urol. 2025 Dec.22(12):846-861. Pubmedid: 40931081.
• Perales MA, Oluwole OO, Patel AR, Ray MD, Rodriguez-Guadarrama YA, Smith NJ, Blissett R, Yang Y, Locke FL. Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma. Transplant Cell Ther. 2025 Dec.31(12):1004.e1-1004.e12. Pubmedid: 40930226.
• Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, Puglianini OC, Freeman C, Ionescu F, Patel K, Ferreri C, Gaballa M, Shune L, McGuirk J, Sidana S, Hovanky V, Khouri J, Raza S, Anwer F, Dima D, Hashmi H, Davis J, Afrough A, Kaur G, Anderson JL, Forsberg P, Herr M, Hansen DK, Hakan Kocoglu M, Sborov D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. Transplant Cell Ther. 2025 Dec.31(12):989-999. Pubmedid: 40972962.
• Parker NH, Ramos JD, Tarhini AA, Schell MJ, Egan KM, Kanetsky PA. A Retrospective Cohort Study of Physical Activity and Survival in Patients Treated with Immune Checkpoint Inhibitors. Cancer Epidemiol Biomarkers Prev. 2025 Dec.34(12):2219-2227. Pubmedid: 40971247. Pmcid: PMC12579459.
• Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec.31(12):1000.e1-1000.e11. Pubmedid: 40754223. Pmcid: PMC12718520.
• Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025 Dec.14(1):2546402. Pubmedid: 40815607. Pmcid: PMC12360205.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis. Int J Mol Sci. 2025 Dec.27(1). Pubmedid: 41515934. Pmcid: PMC12785608.
• Yamoah K, Trivedi P, Awasthi S, Grass GD, Torres-Roca J, Johnstone PA, Dhillon J, Park JY, Davicioni E, Hakansson A, Liu Y, Fink AK, Katende E, Smith R, Putney R, Poch M, Li R, Manley B, Fernandez D, Gage K, Ferguson K, Lu-Yao G, Kim Y, Katsoulakis E, Leone A, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yin V, Burri RJ, Ercole CE, Pow-Sang J. A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study. J Natl Compr Canc Ne. 2025 Dec.24(1). Pubmedid: 41671436.
• Jacobson R, Dineen S, Mullinax J, Martin R, Mishra S, Maurin M, Soundararajan R, Nywening T, Karachristos A, Yadav H, Yeatman T, Fleming J. Collagenolytic Enterococcus faecalis induces DDR1 signaling, proliferation and altered immune infiltrate in colorectal peritoneal metastases. Surg Open Sci. 2025 Dec.28:65-72. Pubmedid: 41322090. Pmcid: PMC12664096.
• Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2025 Dec.15(12):2574. Pubmedid: 41327972.
• Horta M, Augusto BM, Wright KL, Jacobsen P, Gonzalez B, Brandon TH, Vadaparampil ST, Simmons VN. 20 Years in the Making: Advancing Postdoctoral Training in Translational Behavioral Oncology. J Cancer Educ. 2025 Dec. Pubmedid: 41350962.
• El-Atoum M, Chen GL, Bonnewell JP, Segal BH, Almyroudis NG. Incidence Rates of Candida Bloodstream Infections in Patients With Malignancies in a Comprehensive Cancer Centre. Mycoses. 2025 Dec.68(12):e70136. Pubmedid: 41416406. Pmcid: PMC12715748.
• Maura F, Freeman CL, Maclachlan KH, Ilundain ML, Ziccheddu B, Meermeier EW, Garces JJ, Durante M, Lee H, Firestone R, Menges M, Reid K, Diamond B, Papadimitriou M, Silva AS, Sudalagunta PR, Leblay N, Ahn S, Fuller E, Briercheck E, Sharik ME, Du MT, Agius P, Hansen DK, Song X, Zhao X, Meads MB, Teer J, Jelinek T, Hagner P, Baz R, Alsina M, Ramasubramanian AM, Smith E, Giralt SA, Mailankody S, Bergsagel LP, Neri P, Chesi M, Martinez-Climent JA, Locke FL, Bahlis NJ, Landgren O, Hamadeh I, Usmani SZ, Shain KH. Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma. bioRxiv. 2025 Dec. Pubmedid: 41415462. Pmcid: PMC12710967.
• Jazayeri SB, DiNatale RG, Guske C, Harrs C, Linscott J, Xu H, Davaro F, Wen L, Spiess PE, Sexton WJ, Gilbert SM, Zemp L, Poch MA, Li R. Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design. Eur Urol Focus. 2025 Dec. Pubmedid: 41421932.
• Morales MFG, Hogue SR, Pitcher S, Jeong D, Radosavljevic I, Stefanou A, Felder SI, Burns JR, Dowd SE, Vogtmann E, Sinha R, Wang L, Wang X, Permuth JB, Sears CL, Andersen SW, Greathouse KL, Kresovich JK, Friedman MS, Siegel EM, Byrd DA. Survival implications of the age-associated tumor and normal adjacent tissue microbiome among colorectal cancer patients. Gut Pathog. 2025 Dec.17(1):109. Pubmedid: 41437389. Pmcid: PMC12739855.
• Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO. Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation. J Clin Oncol. 2025 Nov.43(31):3369-3380. Pubmedid: 40966481. Pmcid: PMC12700293.
• Zhang Y, Qin D, Ozoya O, Glass F, Sokol L, Ryder CB. Expanded CD4+CD57+ T-large granular lymphocytes: A diagnostic pitfall in blood staging of mycosis fungoides/Sézary syndrome. Am J Clin Pathol. 2025 Nov.164(5):644-649. Pubmedid: 40972673.
• Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. Nat Med. 2025 Nov.31(11):3700-3712. Pubmedid: 40993242. Pmcid: PMC12618235.
• Rollison DE, Garcia MA, Amorrortu RP, Zhao Y, Mittman B, Turner K, Kirtane K, Soliman H, Byrne MM, Meade C, Gwede CK, Eschrich S, Yin J, Stanley NB, Fuzzell L, Hernandez D, Tapia-Kwan E, Vadaparampil ST. Design of a cluster randomized multi-level intervention to decrease barriers to minority cancer patient referral and enrollment to cancer clinical trials: The ACT WONDER2S study. Contemp Clin Trials. 2025 Nov.158:108096. Pubmedid: 40992541. Pmcid: PMC12707367.
• von Deimling M, Furrer M, Bianchi A, Pichler R, Maas M, Tully KH, Longoni M, Mertens LS, Taylor J, Del Giudice F, Li R, Gallioli A, Albisinni S, Crocetto F, Velev M, Afferi L, Mari A, Laukhtina E, Klemm J, Singla N, Fisch M, Spiess PE, Lotan Y, Moschini M, Black PC, Antonelli A, Kiss B, Shariat SF, Pradere B. Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer. BJU Int. 2025 Nov.136(5):911-919. Pubmedid: 40631580. Pmcid: PMC12522521.
• Vicini F, Shah C, Mittal K, Weinmann S, Leo M, Mann GB, Warnberg F, Rabinovitch R, Czerniecki B, Meattini I, Khan AJ, Jhawar S, Gerber N, Willey SC, Borgen P, AlHilli Z, Kruse M, Dabbs D, Shivers SC, Daily A, Whitworth P, Alvarado M, Mouabbi JA, Moran M, Rugo H, O'Shaughnessy JA, Bremer T. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Rec. Int J Radiat Oncol Biol Phys. 2025 Nov.123(4):1090-1101. Pubmedid: 40685017.
• Lee J, Chen F, Lopez-Beltran A, Necchi A, Cimadamore A, Spiess PE, Li R, Roy-Chowdhuri S, Montironi R, Golijanin D, Luchini C, Cheng L. Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. Eur Urol Focus. 2025 Nov.11(6):978-990. Pubmedid: 40753029.
• Lee MS, Hensley PJ, Igel D, Li R, Clark RK, Bingham N, Pallauf M, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Oncologic and survival outcomes in patients undergoing radical nephroureterectomy with preoperative or iatrogenic dialysis dependence. Urol Oncol. 2025 Nov.43(11):662.e9-662.e15. Pubmedid: 40754548.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Nikhil IK, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov.31(11):3668-3674. Pubmedid: 40813711. Pmcid: PMC12419231.
• O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 Nov.60(11):1465-1471. Pubmedid: 40849364. Pmcid: PMC12583187.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov.31(11):3933. Pubmedid: 40858972.
• Cruz-Chamorro R, Bryant JM, Henning J, Robinson LA, Lee DH, Fontaine J, Toloza E, Rosenberg SA, Kim J, Naqa IE, Dilling TJ. Factors impacting cardiac dose and overall survival in post-operative non-small cell lung cancer patients. Radiother Oncol. 2025 Nov.212:111117. Pubmedid: 40854381.
• Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, Miner RE, Teng MN, Pilon-Thomas S, Binning JM. Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer. Mol Ther. 2025 Nov.33(11):5415-5426. Pubmedid: 40873032. Pmcid: PMC12582245.
• Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Finckenstein FG, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025 Nov.43(33):3565-3572. Pubmedid: 40454684. Pmcid: PMC12622280.
• Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
• Obertopp N, Bekker RA, Grass GD, Zelenka T, Thomas A, Potez M, Ali J, Blauvelt J, Hall AM, Hall MS, Chung CH, Enderling H, Pilon-Thomas S. Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes. Int J Radiat Oncol Biol Phys. 2025 Nov.123(4):1102-1115. Pubmedid: 40582598.
• Mamidanna S, Bhandari M, Shah C, Bazile L, Gill SK, Riaz A, Narra LR, Parikh S, Shalaby A, Patel M, Sherwani ZK, Kim J, Deek MP, Jabbour SK, Kumar R. Prophylactic Cranial Irradiation in Small Cell Lung Cancer: Evolution of Evidence, Current Status, and Future Directions. Curr Issues Mol Biol. 2025 Nov.47(12). Pubmedid: 41614762. Pmcid: PMC12731449.
• Parajuli B, Midya V, Kiddle R, De Jager N, Eggers S, Spakowicz D, Hoyd R, Salhia B, Chan CHF, Churchman ML, Rounbehler RJ, Yao S, Rutkowski MR, Tarhini AA, Mudaranthakam DP, Masood A, Bocklage TJ, Lentz RW, Hatoum H, Ilozumba MN, Hardikar S, Ulrich CM, Round JL, Riedlinger G, Shriver CD, Bosch DE. Primary tumor microbiomes predict distant metastasis of colorectal cancer. NPJ Precis Oncol. 2025 Nov.9(1):405. Pubmedid: 41286005. Pmcid: PMC12748615.
• Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD, Lee HC. The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. Blood Cancer J. 2025 Nov.16(1):12. Pubmedid: 41315206. Pmcid: PMC12789570.
• Coukos G, Donia M, Gastman BR, Goff SL, Gros A, Harari A, Hernandez S, Ito F, Maker AV, Mullinax JE, Murthy P, Pai SI, Prabhakaran S, Restifo NP, Silver NL, Marincola Smith P, Turcotte S, Wagner PL, Yang JC, Lotze MT. The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee. J Immunother Cancer. 2025 Nov.13(11). Pubmedid: 41320228.
• Karapetyan L, Kuriakose J, Perez MC, Ali JR, Hall MS, Beatty MS, Otteni CD, Xu J, Kalos D, Moran-Segura C, Vieira E, Adams K, Rodriguez-Alfonso L, DiMaggio EC, Bailey H, Pinilla-Ibarz J, Locke FL, Mullinax JE, Chen PL, Song J, Messina JL, Johnson DB, Morgan DS, Eroglu Z, Khushalani NI, Sondak VK, Sarnaik AA, Tsai K, Mulé JJ, Pilon-Thomas S. Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. Front Immunol. 2025 Nov.16:1718443. Pubmedid: 41333460. Pmcid: PMC12665918.
• Obertopp N, Froid M, Pilon-Thomas S, Basanta D. Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling. bioRxiv. 2025 Nov. Pubmedid: 41332775. Pmcid: PMC12667981.
• Jin N, Hoyd R, Yilmaz AS, Zhu J, Liu Y, Jagjit Singh MS, Grencewicz DJ, Mo X, Kalady MF, Rosenberg DW, Dravillas CE, Singer EA, Carpten JD, Chan CHF, Churchman ML, Denko N, Di Clemente F, Dodd RD, Eljilany I, Fei N, Hardikar S, Ikeguchi AP, Ma A, Ma Q, McCarter MD, Osman AEG, Riedlinger G, Robinson LA, Schneider BP, Tarhini AA, Tinoco G, Figueiredo JC, Zakharia Y, Ulrich CM, Tan A, Spakowicz D. Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer. Cancer Res Commun. 2025 Nov.5(11):1985-1997. Pubmedid: 41134679. Pmcid: PMC12606411.
• Patel AR, Hasegawa K, Pandya S, Shi L, Lau C, Zhao X, Near AM, Locke FL. Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis. J Manag Care Spec Pharm. 2025 Nov.31(11):1110-1122. Pubmedid: 41171063. Pmcid: PMC12577723.
• Falahat R, Mulé JJ. Chemokine/cytokine-releasing biomaterials induce in situ tertiary lymphoid-like structures and enhance antitumor immunity. Proc Natl Acad Sci U S A. 2025 Nov.122(45):e2409560122. Pubmedid: 41183186. Pmcid: PMC12625823.
• Mehta RS, Sparapani RA, Kanakry CG, McCurdy SR, Saultz J, Lazaryan A, Milano F, Lee SJ. Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis. JAMA Oncol. 2025 Nov. Pubmedid: 41196629. Pmcid: PMC12593671.
• Hänggi K, Ruffell B. Protocol for specific induction of apoptosis or necroptosis in established murine tumors. STAR Protoc. 2025 Nov.6(4):104185. Pubmedid: 41205180.
• Locke FL, Nikiforow S, Frigault MJ, Maloney DG, Davila M, Miklos DB, Lin Y, Vong J, Shah NN, Neelapu SS, Welch J, Ng E, Jacobson C, Maus MV. Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies. Transplant Cell Ther. 2025 Nov. Pubmedid: 41207382.
• Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 5.2025. J Natl Compr Canc Ne. 2025 Nov.23(11):426-436. Pubmedid: 41213254.
• Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, Sukrithan V, Ratan A, McCarter M, Salhia B, Colman H, Naqash AR, Puzanov I, Arnold S, Marin-Acevedo JA, Ganesan S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nat Commun. 2025 Nov.16(1):9968. Pubmedid: 41233329. Pmcid: PMC12615696.
• Karapetyan L, Cillo AR, Wang S, Karunamurthy A, Massa RC, Rohatgi A, Deitrick C, Najjar YG, Davar D, Luke JJ, Sander C, Kunning SR, Rose A, Bradley S, Rush E, Joy M, Bao R, Wang H, Vignali DAA, Bruno TC, Kirkwood JM. Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma. medRxiv. 2025 Nov. Pubmedid: 41282765. Pmcid: PMC12637783.
• Faramand RG, Muffly L. Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia. Lancet Haematol. 2025 Nov.12(11):e853-e855. Pubmedid: 41110449.
• Deek RA, Kim J, Kumar R, Medina B, Langenfeld J, Kontopidis I, Lazzaro R, Nie K, Hathout L, Guler O, Onal C, Patel E, Haigentz M, Jabbour SK, Deek MP. Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2025 Nov.26(7):e609-e615.e11. Pubmedid: 40897601.
• Weinfurtner RJ, Ataya D, Funaro K, Bhatt A, Abdalah M, Stringfield O, Raghunand N, Thompson Z, Lee MC, Czerniecki B, Muller AS, Soliman H, Han H. Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy. Clin Imaging. 2025 Nov.127:110618. Pubmedid: 40945432.
• Guerrieri RA, Fischer GM, Cortez JR, Knighton BG, Ledesma DA, Hudgens CW, Delcid YF, Hu Q, Onana CYB, Carapeto FCL, Tezlaff MT, Huse JT, Hwu P, Burton EM, Glitza Oliva IC, Davies MA, Ferguson SD. Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade. Sci Rep. 2025 Oct.15(1):34352. Pubmedid: 41038921. Pmcid: PMC12491558.
• Oseni SO, Wang Y, Hwu P. Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations. Trends Cancer. 2025 Oct.11(10):934-965. Pubmedid: 41046167. Pmcid: PMC12591376.
• Loren AW, Mielcarek M, Bolaños-Meade J, Brammer J, Cowden M, Di Stasi A, El-Jawahri A, Elmariah H, Gundabolu K, Gutman J, Ho V, Hoeg RT, Horwitz M, Jamy O, Kassim A, Dabaja MK, Lee L, Logan A, Luszcak C, Magenau JM, Martin TG, Mittal V, Moreira J, Muffly L, Nakamura R, Nawas M, Nieto Y, Ninos C, Oliai C, Papanicolaou G, Pidala J, Randolph B, Schroeder MA, Tessier J, Topal J, Tzachanis D, Varshavsky-Yanovsky AN, Jones F, Stehman K. Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Ne. 2025 Oct.23(10). Pubmedid: 41067275.
• Baumrucker C, Aiello P, Harris N, Whiting J, Funaro K, Hoover S, Kiluk J, Kruper L, Mallory M, Khakpour N, Laronga C, Czerniecki BJ, Lee MC, Detz D. Identifying Axillary Metastases in Patients with T3 Invasive Lobular Carcinoma. South Med J. 2025 Oct.118(10):687-691. Pubmedid: 41072035.
• Gudenkauf LM, Tometich DB, Hoogland AI, Li X, Kirtane K, Small BJ, Barata A, Gonzalez BD, Jacobs KD, Chung CH, Shafique MR, Gray J, Khushalani NI, Postow MA, Cella D, Webster KA, Dicker AP, Jim HSL. Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical care. Cancer. 2025 Oct.131(20):e70102. Pubmedid: 41045471.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage-Tumor Interactions in the Glioblastoma Microenvironment. Cancers (Basel). 2025 Oct.17(19). Pubmedid: 41097797. Pmcid: PMC12523845.
• Adapa SR, Porshe S, Talada DP, Nywening TM, Anderson ML, Shaw TI, Jiang RHY. Spatial Transcriptomics Reveals Distinct Architectures but Shared Vulnerabilities in Primary and Metastatic Liver Tumors. Cancers (Basel). 2025 Oct.17(19). Pubmedid: 41097737. Pmcid: PMC12523610.
• Peipert JD, Ganatra S, Zhao F, Lee JW, Roydhouse J, Ip EH, O'Connell N, Carlos RC, Graham N, Smith ML, Gareen IF, Tarhini AA, Shanafelt T, Stearns V, Raper PJ, Cella D, Gray R, Wagner LI. Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments. Cancer. 2025 Oct.131 Suppl 2(Suppl 2):e70084. Pubmedid: 41123571. Pmcid: PMC12542925.
• Shah BD, Xue M, Furnback W, Yang K. Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. Future Oncol. 2025 Oct.21(23):3043-3049. Pubmedid: 40916371. Pmcid: PMC12490371.
• Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, Medina T, Ziemer M, Whitman E, Finckenstein FG, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik AA. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). 2025 Oct.45(10):1229-1234. Pubmedid: 40693376. Pmcid: PMC12531414.
• Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Ann Surg Oncol. 2025 Oct.32(11):8211-8219. Pubmedid: 40699532. Pmcid: PMC12494629.
• Ahmed N, Thiruvengadam S, Hamadani M, Hu ZH, Grover NS, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang ML, Kim S, Bye M, Kharfan-Dabaja MA, Sauter CS, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan BR, Nunes A, Dalton DM, Kloos IM, Lee D, Xu H, Pasquini MC, Herrera AF. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025 Oct.9(20):5382-5396. Pubmedid: 40706035. Pmcid: PMC12597645.
• Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 Oct.32(11):8243-8253. Pubmedid: 40705266. Pmcid: PMC12494636.
• Uriepero-Palma A, Marquez ME, Payque E, Mediavilla-Varela M, Gamal W, Maharaj K, Powers JJ, Eksioglu EA, Chavez JC, Sernbo S, Palacios F, Querol Rivas J, Ortega C, Uria R, Dos Santos G, Oliver C, Landoni AI, Sahakian E, Oppezzo P, Pinilla-Ibarz J. Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL. Blood Adv. 2025 Oct.9(20):5219-5233. Pubmedid: 40720748. Pmcid: PMC12550715.
• Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct.146(17):2063-2072. Pubmedid: 40749169.
• Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
• Dineen S, O'Leary C, Rajasekhara S, Mullinax J. Implementation of a Palliative Surgical Oncology Rotation to Complex General Surgical Oncology Fellowship Training. Ann Surg Oncol. 2025 Oct.32(10):7124-7130. Pubmedid: 40849382.
• Othus M, Sharon E, Wu MC, Sondak VK, Ribas A, Patel SP. Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Clin Trials. 2025 Oct.22(5):571-577. Pubmedid: 40099861. Pmcid: PMC12353050.
• Chang SS, Launer B, Narayan V, Patil D, O'Donnell MA, Hensley PJ, Taylor JA, Li R, Fernandez MI, Zhang H, Krishna V, Vrabac D, Abuzeid WM, Nimgaonkar V, Watson D, Royce TJ, Kiedrowski LA, Joshi A, Konety BR, Spiess PE, Williams SB, Packiam VT, Kamat AM, Lotan Y, Daneshmand S. Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stra. Eur Urol. 2025 Oct.88(4):411-413. Pubmedid: 40514253.
• Katims AB, Tin AL, Assel M, Hensley P, Li R, Margulis V, Matin S, Pallauf M, Clark RK, Raman JD, Singla N, Spiess PE, Coleman J. Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration). J Urol. 2025 Oct.214(4):407-414. Pubmedid: 40526449. Pmcid: PMC12355653.
• Schmitz J, Gaskill E, Price S, Cao B, Kim J, Baluch A, Klinkova O, Faramand R, Mishra A, Perez L, Khimani F, Lazaryan A, Ochoa-Bayona JL, Liu H, Mirza AS, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. Bone Marrow Transplant. 2025 Oct.60(10):1383-1386. Pubmedid: 40617898.
• Mehta RS, Aljawai YM, Al-Juhaishi T, Saultz J, Milano F, Kanakry JA, Kanakry CG, Lazaryan A. Role of Donor Cytomegalovirus Serostatus in Cytomegalovirus-Seronegative Recipients of Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis. Transplant Cell Ther. 2025 Sep.31(9):672.e1-672.e9. Pubmedid: 40379049.
• Diamond B, Chahar D, Jain MD, Poos AM, Durante MA, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan KH, Jelinek T, Davies FE, Figura NB, Morgan GJ, Mai EK, Weisel K, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies. Blood Cancer Discov. 2025 Sep.6(5):450-463. Pubmedid: 40402512. Pmcid: PMC12405863.
• Lee SJ, Williams KM, Sarantopoulos S, Kitko CL, Cutler C, Pidala J, Hill GR, DeFilipp Z, Greinix HT, Wolff D, Paczesny S, Cuvelier GDE, Schultz KR, Pavletic SZ. NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update. Transplant Cell Ther. 2025 Sep.31(9):678.e1-678.e16. Pubmedid: 40409691. Pmcid: PMC12354025.
• Ghobadi A, Aldoss I, Maude SL, Bhojwani D, Wayne AS, Bajel A, Dholaria B, Faramand RG, Mattison RJ, Rijneveld AW, Zwaan CM, Calkoen FG, Baruchel A, Boissel N, Rettig MP, Wood B, Jacobs K, Christ S, Irons H, Capoccia B, Masters D, Gonzalez J, Wu T, Del Rosario M, Hamil A, Bakkacha O, Muth J, Ramsey B, McNulty E, Baughman J, Cooper ML, Davidson-Moncada JK, DiPersio JF. Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies. Blood. 2025 Sep.146(10):1163-1173. Pubmedid: 40445850.
• Elmariah H, Kim J, Gonzalez R, DiMaggio E, Sansil S, Mishra A, Faramand R, Perez L, Lazaryan A, Mirza AS, Khimani F, Liu H, Ochoa-Bayona JL, Nieder M, Perna F, Figura N, Robinson TJ, Nishihori T, Anasetti C, Pidala JA, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant. Am J Hematol. 2025 Sep.100(9):1665-1669. Pubmedid: 40492500.
• Hwang SM, Chang S, Rodriguez PC, Cubillos-Ruiz JR. Endoplasmic reticulum stress responses in anticancer immunity. Nat Rev Cancer. 2025 Sep.25(9):684-702. Pubmedid: 40555746. Pmcid: PMC12486299.
• Davis EW, Park MA, Basinski TL, Arnoletti JP, Bloomston M, Carson TL, Biachi De Castria T, Chen DT, Cortizas EM, Crowder SL, Genilo-Delgado M, Douglas WG, Huguet KL, Jiang K, Hodul PJ, Karolak A, Kim DW, Koomen JM, Menon AA, Mo Q, Mok SR, Molina-Vega MA, Moreno-Urazan L, Ahmed S, Parker NH, Pimiento JM, Rasool G, Sparks LM, Stewart PA, Tassielli AF, Teer JK, Trevino JG, Velanovich V, Wang X, Whelan CJ, Judge SM, Judge AR, Fleming JB, Malafa MP, Jeong D, Permuth JB. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep.34(9):1609-1617. Pubmedid: 40553455.
• Locke FL, Le Gall JB, Fisher PW, Neelapu SS. Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching. J Clin Oncol. 2025 Sep.43(25):2834-2835. Pubmedid: 40549998.
• Giridharan T, Suzuki S, Khan ANH, Liu Q, Attwood K, Stokolosa A, Mahan S, Witkiewicz AK, Joseph J, Moysich K, Langermann S, Lovewell R, Flies D, Myint H, Odunsi K, Emmons TR, Yaffe MB, Zsiros E, Dey P, McGray AJR, Segal BH. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. J Immunol. 2025 Sep.214(9):2464-2479. Pubmedid: 40560129. Pmcid: PMC12481037.
• Alonso-Matilla R, Pedro DI, Pepe A, Serrano-Velez J, Dunne M, Nguyen DT, Sawyer WG, Provenzano PP, Odde DJ. Biophysical modeling identifies an optimal hybrid amoeboid-mesenchymal mechanism for maximal T cell migration speeds. bioRxiv. 2025 Nov. Pubmedid: 39026744. Pmcid: PMC11257493.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies. Cells. 2025 Sep.14(18). Pubmedid: 41002423. Pmcid: PMC12468907.
• Jain MD, Cools-Lartigue J. Immune dysfunction after cancer remission: scar or disease?. Blood. 2025 Sep.146(11):1255-1257. Pubmedid: 40932742.
• Hijazi A, Locke FL, Scholler N, Mattie M, Filosto S, Bedognetti D, Galon J. Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma. Clin Cancer Res. 2025 Sep.31(18):3834-3843. Pubmedid: 40622821. Pmcid: PMC12434396.